

Signature Page

AMBLYOPIA TREATMENT STUDY

A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Protocol Identifying Number: ATS23

Version Number: 1.0

01 April 2024

JCHR Principal Investigator	
Name, degree	Robert Henderson, MS
Signature/Date	
Protocol Chair(s) (as applicable)	
Name, degree	Aparna Raghuram, OD, PhD
Signature/Date	
Protocol Chair(s) (as applicable)	
Name, degree	Kammi B. Gunton, MD
Signature/Date	

AMBLYOPIA TREATMENT STUDY

A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Protocol Identifying Number: ATS23

Version Number: 1.0

01 April 2024

KEY ROLES

JCHR Principal Investigator	
Name, degree	Robert Henderson, MS
Title	Principal Investigator
Institution Name	Jaeb Center for Health Research 15310 Amberly Drive, Suite 350 Tampa, FL 33647 Phone: 1-888-797-3344 Fax: 1-888-697-3344 Email: rhenderson@jaeb.org http://www.pedig.net
Protocol Co-Chair	
Name, degree	Aparna Raghuram, OD, PhD
Title	Protocol Co-Chair
Institution Name	Boston Children's Hospital/ Harvard Medical School Department of Ophthalmology, Fegan 4, 4th Floor 300 Longwood Avenue Boston, MA 02115 Phone: 1-617-355-6401 Fax: 1-617-730-0392 Email: aparna.raghuram@childrens.harvard.edu
Protocol Co-Chair	
Name, degree	Kammi B. Gunton, MD
Title	Protocol Co-Chair
Institution Name	Wills Eye Hospital 840 Walnut Street Suite 1530 Philadelphia, PA 19107 Phone: 1-215-928-3914 Fax: 1-215-928-3983 Email: kbgunton@comcast.net

VERSION HISTORY

VERSION NUMBER	AUTHOR	APPROVER	EFFECTIVE DATE	REVISION DESCRIPTION
1.0	R. Kraker	R. Henderson	01Apr2024	

*Version in effect at study initiation

TABLE OF CONTENTS

CHAPTER 1: BACKGROUND INFORMATION 15

1.1 Epidemiology and Clinical Characteristics 15

1.2 Current Practice 15

 1.2.1 Monocular Penalization..... 15

 1.2.2 Dichoptic Treatments 15

 1.2.2.1 Dichoptic Games..... 15

 1.2.2.2 Dichoptic Movies/Shows 16

1.3 Rationale for the Present Study 16

1.4 Potential Risks and Benefits of Study Treatment 17

 1.4.1 Known Potential Risks 17

 1.4.1.1 Patching..... 17

 1.4.1.2 Luminopia 18

 1.4.2 Known Potential Benefits..... 18

 1.4.3 Risk Assessment..... 18

1.5 General Considerations..... 19

CHAPTER 2: STUDY ENROLLMENT AND SCREENING 20

2.1 Participant Recruitment and Enrollment 20

 2.1.1 Informed Consent and Authorization Procedures 20

2.2 New or Change in Spectacle Correction If Needed..... 20

2.3 Participant Inclusion Criteria..... 21

2.4 Participant Exclusion Criteria..... 22

2.5 Procedures at Enrollment Visit..... 23

 2.5.1 Historical Information 23

 2.5.2 Ability to Use Luminopia..... 23

 2.5.3 Clinical Testing 23

2.6 Randomization of Eligible Participants 25

CHAPTER 3: RANDOMIZED TRIAL PROCEDURES 26

3.1 Treatment..... 26

 3.1.1 Luminopia Group 26

 3.1.2 Patching Group..... 26

3.2 Phone Call 26

3.3 Follow-up Schedule Through 26-Week Primary Outcome 26

 3.3.1 Resolution of Amblyopia at 13-Week Office Visit..... 27

3.4 Continued Follow-up Post 26-Week Primary Outcome	27
3.4.1 Resolution of Amblyopia at 39-Week Office Visit	27
3.5 Follow-up Visit Testing Procedures	27
3.5.1 Masked Examiner	29
3.6 Non-Study Visits and Treatment	29
3.7 Management of Refractive Error	29
3.8 Management of Strabismus	30
CHAPTER 4: STUDY DEVICE.....	31
4.1 Description of the Luminopia Device.....	31
4.1.1 Headset	31
4.1.2 Internet Requirements	31
4.2 Device Delivery and Return	31
4.3 Device Accountability Procedures	31
4.3.1 Device Failure	31
4.3.2 Participant Access to Study Device After Primary Outcome Visit	32
CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES	33
5.1 Questionnaires	33
5.2 Clinical Assessments	33
CHAPTER 6: MISCELLANEOUS CONSIDERATIONS.....	35
6.1 Contacts by the Jaeb Center for Health Research and Sites	35
6.2 Participant Compensation	35
6.3 Cost of Treatment	35
6.4 Participant Withdrawal	35
6.5 Confidentiality	35
CHAPTER 7: UNANTICIPATED PROBLEM AND ADVERSE EVENT REPORTING.....	36
7.1 Unanticipated Problems.....	36
7.2 Adverse Events	36
7.2.1 Reportable Adverse Events	36
7.2.2 Safety Oversight	36
7.2.3 Stopping Criteria	37
7.2.4 Participant Discontinuation of Study Treatment	37
CHAPTER 8: STATISTICAL CONSIDERATIONS.....	38
8.1 Statistical and Analytical Plans	38
8.2 Study Objective and Statistical Hypothesis	38
8.2.1 Primary Efficacy Outcome	38

8.3 Sample Size	39
8.3.1 Effect of PATCHING.....	39
8.3.2 Effect of LUMINOPIA.....	39
8.3.3 Selection of Noninferiority Margin.....	40
8.3.4 Sample Size Calculations and Assumptions.....	40
8.3.5 Power for Superiority	41
8.4 Outcome Measures	41
8.5 Analysis Datasets and Sensitivity Analyses	42
8.6 Analysis of the Primary Efficacy Outcome	42
8.7 Analysis of the Secondary Efficacy Outcomes	43
8.7.1 Pediatric Eye Disease Questionnaire (PedEyeQ)	43
8.8 Intervention Adherence	43
8.9 Protocol Adherence and Retention	44
8.10 Intercurrent Events	44
8.11 Safety Analyses	44
8.12 Baseline Descriptive Statistics.....	45
8.13 Planned Interim Analyses	45
8.14 Subgroup Analyses	45
8.15 Multiple Comparison/Multiplicity.....	45
8.16 Exploratory Analyses	46
8.16.1 Mean Change in Distance VA at 13 Weeks	46
8.16.2 Mean Change in Distance VA over 26 weeks (area under the curve).....	46
8.16.3 Improvement of Amblyopic-eye Distance VA by 2 or More Lines	46
8.16.4 Binocular Function	46
8.16.5 Resolution of Amblyopia at 13 weeks and 26 weeks	46
8.16.6 Treatment Impact Questionnaire	47
8.16.7 Improvement with Dichoptic Therapy after PATCHING	47
CHAPTER 9: DATA COLLECTION AND MONITORING	48
9.1 Case Report Forms and Other Data Collection	48
9.2 Study Records Retention	48
9.3 Quality Assurance and Monitoring.....	48
9.4 Protocol Deviations	49
CHAPTER 10: ETHICS/PROTECTION OF HUMAN PARTICIPANTS.....	50
10.1 Ethical Standard.....	50
10.2 Institutional Review Boards	50
10.3 Informed Consent Process	50

JAEB CENTER FOR HEALTH RESEARCH

10.3.1 Consent Procedures and Documentation..... 50
10.4 Participant and Data Confidentiality 51
10.5 Future Use of Data..... 51
CHAPTER 11: REFERENCES..... 52

LIST OF ABBREVIATIONS

ABBREVIATION	DEFINITION
ANCOVA	Analysis of covariance
ATS	Amblyopia Treatment Study
BCVA	Best corrected visual acuity
CI	Confidence interval
CFR	Code of Federal Regulations
CRF	Case report form
D	Diopter
DHHS	Department of Health and Human Services
DSMC	Data safety and monitoring committee
eCRF	Electronic case report form
FDA	Food and Drug Administration
GCP	Good clinical practice
ICH	International Council for Harmonisation
IOD	Interocular difference
IRB	Institutional Review Board
JCHR	Jaeb Center for Health Research
logMAR	Logarithm of the minimal angle of resolution
NIH	National Institutes of Health
ODM	Occlusion dose monitor
PACT	Prism and alternate cover test
PedEyeQ	Pediatric Eye Questionnaire
PEDIG	Pediatric Eye Disease Investigator Group
QA	Quality assurance
QC	Quality control
RBM	Risk based monitoring
RCT	Randomized clinical trial
SAP	Statistical Analysis Plan
SPCT	Simultaneous prism and cover test
VA	Visual Acuity

PROTOCOL SUMMARY

Title	A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age.
Précis	<p>Current treatments for amblyopia have limited effectiveness in a notable proportion of young children. In addition, the standard treatment of patching may be associated with adverse psychosocial effects. Home-based dichoptic movies/shows present an appealing alternative to patching, but there are few data on comparative effectiveness.</p> <p>Dichoptic movies/shows with Luminopia technology show promise of better adherence, and an easier treatment experience.</p> <p>If dichoptic therapy using Luminopia is confirmed to be non-inferior to standard part-time patching for best-corrected visual acuity, this study will have provided evidence to support Luminopia as a reasonable alternative to patching in young children. In addition, we plan to assess treatment impact and quality of life to provide data on whether there are advantages to Luminopia.</p>
Investigational Device	Luminopia digital therapeutic system.
Primary Objective	In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Study Design	Multicenter, randomized clinical trial.
Number of Sites	The study is open to all clinical sites approved to participate in the PEDIG network.
Endpoints	<p>Primary Efficacy Outcome:</p> <ul style="list-style-type: none"> Change in amblyopic eye logMAR distance VA between randomization and 26 weeks. <p>Key Secondary Efficacy Outcomes:</p> <ul style="list-style-type: none"> Functional Vision, Social, and Frustration/Worry quality of life domains as measured by the Pediatric Eye Questionnaire (PedEyeQ). <p>Key Safety Outcomes:</p> <ul style="list-style-type: none"> Change in fellow eye logMAR distance VA between randomization and 26 weeks. Proportion of participants with no strabismus who develop a new strabismus. Proportion of participants with strabismus who develop a worsening strabismus $\geq 10\Delta$. Proportion of participants with parental report of diplopia more than once per week. Proportion of participants reporting headache, eyestrain, nausea, seizures, dizziness, increase in frequency of night terrors, or skin irritation.

JAEB CENTER FOR HEALTH RESEARCH

Population	<p>Key Inclusion Criteria:</p> <ul style="list-style-type: none"> • Age 4 to 7 years. • Amblyopia associated with anisometropia, strabismus ($\leq 5\Delta$ at distance and near measured by SPCT), or both. • Amblyopic-eye VA of 20/40 to 20/200 inclusive by ATS-HOTV. • Age normal VA in the fellow eye by ATS-HOTV (20/40 or better if age 4 years, 20/32 or better if age 5-6 years, 20/25 or better if age 7 years). • Interocular difference in VA of 3 logMAR lines or more by ATS-HOTV. • Spectacles/contact lens correction (if required) worn for at least 18 weeks, or until stability of VA is demonstrated (<1-line change by the same testing method measured on 2 exams at least 9 weeks apart). • Interpupillary distance of 52mm to 72mm inclusive. • No treatment with cycloplegic eyedrops (e.g., atropine) in the last 2 weeks. • No more than 2 weeks (cumulative) prior dichoptic treatment. • No diplopia by parental report (defined as no more than once per week). • No myopia greater than -6.00D SE in either eye.
Sample Size	238 total participants (119 in each treatment group)
Phase	Phase III Randomized Clinical Trial
Treatment Groups	<p>Random assignment (1:1) to:</p> <ul style="list-style-type: none"> • Luminopia Group: watching dichoptic movies/shows wearing the Luminopia headset prescribed 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day) 6 days a week with optical correction, if needed. • Patching Group: patching of the fellow eye 2 hours per day (treatment time can be split into shorter sessions totaling 2 hours each day) 7 days per week with optical correction, if needed.
Participant Duration	If randomized, participation in the study will last 1 year or less.
Study Duration	Thirty-seven (37) months from first enrollment to last participant visit (25 months to recruit, followed by 12 months of follow up).
Protocol Overview/Synopsis	<p>Participants eligible for the study will be randomly allocated (1:1) to receive either dichoptic treatment while wearing the Luminopia headset or patching treatment of the fellow eye for amblyopia with clinical assessments at 13, and 26-weeks post-randomization.</p> <p>At the 26-week primary outcome visit, participants who were randomly assigned to receive patching treatment with an IOD of 1 logMAR line or more, will be offered Luminopia dichoptic therapy and if they accept, followed forward with visits at 39- and 52-weeks post-randomization.</p> <p>The study will end for all other participants.</p>

STUDY SUMMARY FLOW CHART

New or Change in Spectacle Correction if Needed

- Participants meeting all eligibility criteria except for refractive error may be prescribed spectacles paid for by the study if investigator verifies visual acuity with the intended spectacle prescription is expected to meet eligibility criteria.
- Participants will return for standard of care visits until they meet eligibility criteria below and complete enrollment testing in new spectacles.

Major Eligibility Criteria

- Age 4 to 7 years
- Amblyopia associated with anisometropia, strabismus ($\leq 5\Delta$ at distance and near, by SPCT), or both.
- No more than 2 weeks (cumulative) prior dichoptic treatment
- No treatment with cycloplegic eyedrops (e.g., atropine) in the last 2 weeks
- Spectacles/contact lens correction (if required) worn for at least 18 weeks, or demonstrated stability of amblyopic eye VA (< 1 -line change by the same testing method measured on 2 exams at least 9 weeks apart)
- Visual acuity in the amblyopic eye of 20/40 to 20/200 inclusive by ATS-HOTV
- Interocular difference in VA of 3 logMAR lines or more by ATS-HOTV.
- Age normal VA in the fellow eye (20/40 or better if age 4, 20/32 or better if 5-6, 20/25 or better if age 7) by ATS-HOTV
- No diplopia by parental report (defined as no more than once per week)
- No myopia greater than -6.00D SE in either eye
- Interpupillary distance of 52mm to 72mm inclusive
- History of light-induced seizures.

Baseline Measurements (with best correction)

- Monocular distance VA testing (ATS-HOTV)
- Binocular function testing (Randot Preschool, if nil, test Butterfly; if nil, test Worth 4-shape)
- Ocular alignment testing (cover/uncover, SPCT, PACT) at distance and near
- PedEyeQ Functional Vision, Social, and Frustration/Worry domains

Randomize

Luminopia Group

Dichoptic movies/shows 1 hour per day,
6 days per week

Patching Group

Patch fellow eye 2 hours per day,
7 days per week

1-Week Phone Call 7 to 13 days from Randomization


Inquire if any problems with randomized treatment (completed by site personnel)

Follow-Up Exam (13 Weeks \pm 2 weeks from Randomization)

- Assessment of Diplopia and Adverse Events
- Treatment Impact Questionnaire
- PedEyeQ Social and Frustration Worry Domains
- Monocular distance VA testing (ATS-HOTV) (**Masked**)
- Binocular function testing (Randot Preschool; if nil, test Butterfly; if nil, test Worth 4-shape) (**Masked**)
- Ocular alignment testing (cover/uncover, SPCT, PACT) at distance and near
- Stop randomized treatment if amblyopia resolves (defined as ≤ 0 logMAR lines IOD with fellow eye VA no worse than 1-line below baseline).

Primary Outcome Exam (26 Weeks \pm 2 weeks from Randomization)

- Assessment of Diplopia and Adverse events
- Treatment Impact Questionnaire
- PedEyeQ Visual Function Domain
- Monocular distance VA testing (ATS-HOTV) (**Masked**)
- Binocular function testing (Randot Preschool; if nil, test Butterfly; if nil, test Worth 4-shape) (**Masked**)
- Ocular alignment testing (cover/uncover, SPCT, PACT) at distance and near



SCHEDULE OF STUDY VISITS AND PROCEDURES

Visit	Informed Consent	Demographics / Medical History	Distance VA	Binocular Function Testing	Ocular Alignment	PedEyeQ Functional Vision	PedEyeQ Social/Frustration/Worry	Binocular Diplopia Questionnaire	Adverse Events Questionnaire	Treatment Impact Questionnaire
Enrollment Visit	X	X	X	X	X	X	X	X		
1-week Call										
13-week Visit			X masked	X masked	X		X	X	X	X
26-week Visit			X masked	X masked	X	X		X	X	X
27-week Call*										
39-week Visit†			X	X	X			X	X	
52-week Visit†			X	X	X			X	X	

*27-week phone call timed 7 to 13 days after the 26-week primary outcome only for participants assigned to patching who have residual amblyopia and accept treatment with Luminopia at the 26-week primary outcome.

†The 39-week and 52-week post-randomization visits are completed by any participant assigned to patching who has residual amblyopia and accepts treatment with Luminopia at the 26-week primary outcome.

Chapter 1: Background Information

1.1 Epidemiology and Clinical Characteristics

Amblyopia is the most common cause of reduced monocular visual acuity (VA) in children and young adults, with estimates of prevalence ranging from 1% to 5%.^{1,2} Common risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced VA, amblyopia may also be associated with dysfunctions of accommodation, fixation, binocularity, vergence, reading speed and fluency, and contrast sensitivity.³⁻¹²

1.2 Current Practice

1.2.1 Monocular Penalization

The current foundation of amblyopia treatment is optical correction (when there is uncorrected refractive error) followed, if needed, by part-time patching or atropine penalization of the fellow eye.¹³⁻¹⁸ This treatment approach has been shown to be effective in many younger children (3 to <7 years),¹³⁻¹⁸ but residual amblyopia (20/32 or worse) is present in approximately 54% at age 10 years¹⁹ and 40% at age 15 years.²⁰

A possible explanation for failure of part-time patching treatment in some younger children is poor adherence with prescribed treatment regimens.^{21,22} Nevertheless, data from studies using occlusion dose monitors^{23,24} indicate that many children who successfully adhere to prescribed part-time patching still fail to respond fully. Such data suggest that part-time patching may simply be inadequate in some young children with amblyopia.

1.2.2 Dichoptic Treatments

An alternative treatment approach that has gained momentum in recent years is dichoptic therapy.²⁵ Although monocular penalization has been the predominant amblyopia treatment approach for many years, some have advocated that a dichoptic (binocular) approach has additional value.²⁶ Dichoptic treatments for amblyopia provide simultaneous but separate and independent stimulation to each eye, incorporating binocular elements, but modifying the input to the sound eye by introducing blur, reduced contrast, and/or reduced luminance. Dichoptic treatment strategies may also differentially modify central versus peripheral vision. The neurophysiological basis for dichoptic treatment is supported by evidence that binocular cortical mechanisms remain intact even in adults with strabismic amblyopia.²⁷

Over the past 20 years, dichoptic treatments have evolved from office-based technologies²⁸⁻³⁰ to those that can be conducted in the home. Home-based technologies have many advantages, including convenience and reduced cost associated with less in-office care-provider time.

Current home-based dichoptic treatments typically utilize games, movies, or web-based content. Both dichoptic games and dichoptic movies have been previously studied to a limited extent in younger children with amblyopia.^{25,31-34}

1.2.2.1 Dichoptic Games

PEDIG has previously evaluated two dichoptic iPad games as treatment for amblyopia in RCTs in younger children. In ATS18,³¹ the Tetris falling blocks game was found *not* to be non-inferior to patching; however, only 22% completed >75% of prescribed gameplay (objectively

47 monitored).³⁴ In the ATS20 younger cohort of 4- to 6-year-olds,³² binocular Dig Rush treatment
48 resulted in greater improvement in amblyopic-eye VA at 4 weeks but not at 8 weeks compared
49 with continued spectacles alone. Only half of 46 participants (57%) completed >75% of
50 prescribed gameplay (objectively monitored) over the entire 8 weeks.³²

51
52 Another RCT of dichoptic game play reported similar problems with adherence in younger
53 children.³³ Likewise, a study evaluating barriers to successful dichoptic video game play³⁵
54 reported that inability to understand game requirements was a significant barrier to successful
55 treatment in children <5.5 years of age.

56
57 These previous data strongly suggest that poor comprehension and poor adherence with game
58 play are factors that have likely contributed to failure to show a benefit of this modality of
59 dichoptic treatment.

60 61 **1.2.2.2 Dichoptic Movies/Shows**

62 Home-based dichoptic movies have been evaluated in younger children in a small number of
63 previous randomized trials.^{36,37} Luminopia is a dichoptic movie technology (often termed a
64 digital therapeutic with software as the medical device) available for use in the USA since 2022
65 and has been approved by the FDA for the treatment of amblyopia in children 4 to 7 years of age.

66
67 Luminopia displays a large library of web-based video content through a virtual reality (VR)
68 headset, utilizing computational algorithms to split the source video into 2 streams (one to each
69 eye) and modify the input in real time. Contrast in the sound eye is reduced to 15% and a series
70 of 6 different dichoptic masks overlay the video content, rotating every 30 seconds.

71
72 Xiao et al³⁶ conducted a randomized trial comparing dichoptic movies using the Luminopia
73 device versus continued glasses alone. Of 103 enrolled children (aged 4 to 7 years) 52 were
74 randomly assigned to continued glasses and 51 to dichoptic movies using Luminopia 1 hour/day,
75 6 days a week. At the 12-week outcome, mean amblyopic eye VA had improved 1.8 lines (95%
76 CI: 1.4 to 2.3 lines; n=45) in the Luminopia group and 0.8 lines (95% CI: 0.4 to 1.3 lines; n=45)
77 in the continued glasses group. At the planned interim analysis, the difference between groups
78 was significant favoring Luminopia by 1.0 line (P=0.001; 96.14% CI: 0.3 to 1.6 lines) and the
79 study was stopped early for success. Median adherence with Luminopia (objectively monitored
80 by the device) was 88% over 12 weeks (IQR, 61 to 99%).

81
82 In a preceding non-randomized study,³⁸ Xiao et al prescribed Luminopia 1 hour/day for 12
83 weeks to 90 children 4- to 12-years of age (mean 6.7 ± 2.0 years) with amblyopia. Overall
84 (n=74) the mean amblyopic-eye VA improved from 0.50 ± 0.15 to 0.35 ± 0.21 logMAR (1.5
85 logMAR lines, 95% CI: 1.2-1.8 lines, $P < 0.001$) over 12 weeks.³⁸ Median adherence (objectively
86 monitored by the device) was 86% (IQR, 70% to 97%).

87 88 **1.3 Rationale for the Present Study**

89 Current treatments for amblyopia have limited effectiveness in some young children. In a
90 previous large, multicenter RCT, home-based dichoptic movies were shown to be superior to
91 continued glasses alone, but treatment effectiveness compared with patching has not yet been

92 established. It is possible that dichoptic movies/shows are as effective as patching, in which case
 93 they would provide an appealing alternative treatment.

94
 95 Standard patching treatment may also be associated with adverse effects including negative
 96 psychosocial experiences, bullying, and social stigma.³⁹⁻⁴³ There are few direct measures of
 97 treatment impact and there is a need for instruments that assess the impact a treatment has on the
 98 child and their family. Such an assessment is of value especially for treatments that may be
 99 similar regarding effectiveness but differ regarding treatment experience. Dichoptic
 100 movies/shows with Luminopia technology show promise of better adherence and an easier
 101 treatment experience.

102
 103 Treatment outcomes are typically measured only in terms of monocular VA despite evidence that
 104 amblyopia impacts many other visual functions.³⁻¹² An expanded assessment of amblyopia
 105 treatment outcomes, including evaluation of functional vision and quality of life, is important for
 106 future practice and research. Such testing will lead to an improved understanding of the wider-
 107 reaching benefits of amblyopia treatment and enable further exploration of possible differential
 108 treatment benefits with different modalities.

109
 110 In summary, while current treatment approaches are moderately effective in many younger
 111 children with amblyopia, the high prevalence of residual amblyopia and the challenges
 112 associated with patching treatment call for consideration of alternative, age-appropriate
 113 treatments. Treatments less onerous than patching need to be considered even if treatment
 114 outcomes are only equally effective.

115
 116 If dichoptic therapy using the Luminopia digital therapeutic system is confirmed to be non-
 117 inferior to standard part-time patching for improving amblyopic eye best-corrected VA, this
 118 study would provide evidence to support Luminopia as a reasonable alternative to patching in
 119 young children. In addition, we plan to assess: 1) treatment impact to provide data on whether
 120 there are advantages to Luminopia regarding treatment burden and treatment difficulty, 2) impact
 121 on functional vision and 3) impact on social and frustration / worry quality of life concerns.

122
 123 **1.4 Potential Risks and Benefits of Study Treatment**

124
 125 **1.4.1 Known Potential Risks**

126
 127 **1.4.1.1 Patching**

128 Patching treatment may potentially cause a decrease of VA in the non-amblyopic eye (reverse
 129 amblyopia), but this is extremely unlikely when the fellow eye has several hours without
 130 occlusion each day, and should it occur, is almost always reversible. If reverse amblyopia occurs,
 131 investigators should contact one of the protocol chairs to discuss future management.

132
 133 Skin irritation may develop due to the adhesive patch, but this is expected to be rare with only 2
 134 hours per day of patching. If irritation develops the participant will be provided with a fabric
 135 patch to wear on their glasses (plano glasses will be provided for children who are not already
 136 wearing glasses).

138 Diplopia with patching is expected to be rare based on our experience in ATS18 in which only
 139 2% reported diplopia at a frequency of once per week (the maximum frequency reported).³¹
 140

141 Likewise, the development of a new strabismus or worsening of a preexisting strabismus is
 142 expected to be rare with a rate of 5.9% found in the patching group in ATS18.³¹
 143

144 **1.4.1.2 Luminopia**

145 In a previous randomized clinical trial evaluating Luminopia vs continued glasses alone in
 146 children aged 4 to 7 years³⁶, 10 (20%) of 51 patients experienced non-serious adverse events in
 147 the treatment group vs. 7 (13%) of 54 patients in the continued glasses group. In the Luminopia
 148 treatment group adverse events were new heterotropia in 3 (6%), worsening VA in the
 149 amblyopic eye in 2 (4%), worsening VA in the fellow eye in 2 (4%), headache in 4 (8%),
 150 eyestrain in 1 (4%), with single cases each of dizziness, increase in frequency of night terrors,
 151 eye twitching, and facial redness.
 152

153 In the continued glasses group adverse events were diplopia in 1 (2%), new heterotropia in 2
 154 (4%), worsening heterotropia in 1 (2%), worsening VA in the amblyopic eye in 4 (7%), headache
 155 in 1 (2%) and pain from glasses in 1 (2%). No serious adverse events were reported. The most
 156 frequent non-serious adverse event potentially related to Luminopia was headache (8%).

157 In a preceding non-randomized study evaluating 90 participants aged 4 to 12 years,⁴⁰ the most
 158 common adverse events were headaches (n=6), eye strain (n=3), blurry vision (n=2), and
 159 worsening VA (n=2). One participant developed a new strabismus. All adverse events were
 160 graded as mild in severity.
 161

162 The Luminopia headset may become warm during normal usage. If the surface touching the face
 163 feels hot, the participant should stop using the headset immediately and wait for it to cool down
 164 before re-using.
 165

166 Luminopia treatment is considered “digital media” use for children. An American Academy of
 167 Pediatrics (AAP) policy statement recommends that children 2 to 5 years should be limited to no
 168 more than 1 hour per day of digital media use, noting that heavy media use during preschool
 169 years is associated with small but significant increases in BMI and sets the stage for weight gain
 170 later in childhood. During the informed consent process, parents of children aged 4 or 5 years
 171 will be advised of these potential risks associated with digital media if they are prescribed
 172 Luminopia therapy.
 173

174 **1.4.2 Known Potential Benefits**

175 The potential benefit of treatment with patching or treatment with Luminopia is improvement in
 176 amblyopic eye VA.
 177

178 **1.4.3 Risk Assessment**

179 Luminopia is a software-only digital therapeutic designed to be used with commercially
 180 available Head-Mounted Displays (HMDs) which are compatible with a software application.
 181 Luminopia is approved by the FDA and indicated for improvement in visual acuity in amblyopia
 182 patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received
 183 treatment instructions (frequency and duration) as prescribed by a trained eye-care professional.

184
185 The expected adverse events from Luminopia are summarized in 1.4.1.2 and do not pose a
186 greater risk than what the typical child would experience in their normal day-to-day activities
187 (e.g., wearing glasses, wearing small adhesives like band aids, watching television, playing
188 videogames, etc.).

189
190 The safety of Luminopia beyond 12 weeks is unknown; however, the expected adverse events
191 between 12 weeks and 26 weeks in the current study are expected to be similar in type and
192 severity to the type and severity summarized in 1.4.1.2.

193
194 Since Luminopia does not pose a significant risk to participants, the Sponsor has determined that
195 Luminopia is not a significant risk device.

196
197 The expected adverse events from patching are summarized in 1.4.1.1 and are non-significant.

198
199 The Sponsor has determined that the protocol's level of risk is consistent with 45 CFR 46.404
200 and 21 CFR 50.51, which indicates research not involving greater than minimal risk.

201
202 **1.5 General Considerations**

203 The study is being conducted in compliance with the policies described in the study policies
204 document, with the ethical principles that have their origin in the Declaration of Helsinki, with
205 the protocol described herein, and with the standards of Good Clinical Practice (GCP).

206
207 The protocol is not considered a significant risk device study, since Luminopia is a non-invasive
208 product that has been approved by the U.S. Food and Drug Administration (FDA) as treatment
209 for amblyopia in children aged 4 to 7 years for up to 12 weeks. Therefore, an investigational
210 device exemption (IDE) from the FDA is not required to conduct the study. However, the study
211 must still comply with the abbreviated requirements of 21 CFR 812.2(b) as a non-significant risk
212 device under an investigation to evaluate safety and efficacy as used specified in accordance with
213 this protocol.

Chapter 2: Study Enrollment and Screening

214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258

2.1 Participant Recruitment and Enrollment

The study plans to enroll a minimum of 238 participants. As the enrollment goal approaches, sites will be notified of the end date for recruitment. Study participants whose parents have signed an informed consent form (and child has signed assent form, if required) can be enrolled up until the end date, which means the recruitment goals might be exceeded; however, total recruitment will not exceed 250 participants.

Study participants will be recruited from approximately 70 clinical centers in North America. All eligible participants will be included without regard to sex, race, or ethnicity. There is no restriction on the number of participants to be enrolled or randomized by each site toward the overall recruitment goal.

2.1.1 Informed Consent and Authorization Procedures

A child is considered for the study after undergoing a routine eye examination as part of standard of care that identifies amblyopia appearing to meet the eligibility criteria. Children may also be referred to a study investigator from another eye-care or health-care provider. The study will be discussed with the child’s parent(s) or legal guardian(s) (referred to subsequently as parent(s)). Parent(s) who express an interest in the study will be given a copy of the informed consent form to read. Written informed consent and assent must be obtained from a parent prior to performing any study-specific procedures that are not part of the child’s routine care and/or collecting any data for the study.

If the participant and/or parents are not fluent in written and spoken English, then the consent and/or assent forms must be translated into a language of fluence for the participant/parent. Further, a qualified interpreter must be available for the consent process and for all subsequent study-related interactions.

A participant is considered enrolled when the informed consent and assent forms have been signed, as applicable.

2.2 New or Change in Spectacle Correction If Needed

New spectacles or a change in spectacles may be prescribed for participants who have not had a cycloplegic refraction within 7 months *OR* if their current spectacles do not meet spectacle tolerance criteria (2.3 #6) *OR* in cases where the investigator determines that updating the spectacles is necessary for best clinical care, *IF* they *ALSO* meet *ALL* the other inclusion criteria (2.3) while wearing their current refractive correction.

The prescribed spectacles must be based upon a cycloplegic refraction performed on the day of enrollment or within 7 months and must meet eligibility criteria in 2.3 #6. If new spectacles are prescribed and paid for by the study, the investigator should ensure that visual acuity is still expected to meet eligibility criteria in 2.3 #2. As needed, VA should be measured (using the investigator’s preferred VA testing method) in the intended spectacle prescription if the child is not cyclopleged or in the full cycloplegic refractive error if the child is cyclopleged.

259
 260 The participant will return for standard of care visits until they meet eligibility criteria (including
 261 stability criteria) below in 2.3 #6.

262
 263 Any new contact lenses or change to contact lenses will NOT be paid for by the study.

264
 265 **2.3 Participant Inclusion Criteria**
 266 At the time of enrollment, individuals must meet all the following inclusion criteria to be eligible
 267 to participate in the study.

- 268
 269 1. Age 4 to 7 years.
 270 2. Visual acuity, measured in each eye without cycloplegia in current refractive correction
 271 (if applicable) using the ATS-HOTV VA protocol on a study-approved device displaying
 272 single surrounded optotypes, as follows:
 273 a. VA in the amblyopic eye 20/40 to 20/200 inclusive.
 274 b. Age-normal VA in the fellow eye.^{44,45}
 275 • 4 years: 20/40 or better; 5-6 years: 20/32 or better; 7 years: 20/25 or better
 276 c. Interocular difference ≥ 3 logMAR lines (i.e., amblyopic eye VA at least 3 logMAR
 277 lines worse than fellow eye VA).
 278 3. Amblyopia associated with strabismus, anisometropia, or both (previously treated or
 279 untreated).
 280 a. Criteria for strabismic amblyopia: At least one of the following must be met:
 281 • Presence of a heterotropia on examination at distance or near fixation (with
 282 optical correction), must be ≤ 5 prism diopters (Δ) by SPCT at distance and near
 283 fixation.
 284 • Documented history of strabismus which is no longer present (which in the
 285 judgment of the investigator could have caused amblyopia).
 286 b. Criteria for anisometropia: At least one of the following criteria must be met:
 287 • ≥ 1.00 D difference between eyes in spherical equivalent (SE).
 288 • ≥ 1.50 D difference in astigmatism between corresponding meridians in the two
 289 eyes.
 290 c. Criteria for combined-mechanism: Both of the following criteria must be met:
 291 • A criterion for strabismus is met (see above).
 292 • ≥ 1.00 D difference between eyes in spherical equivalent OR ≥ 1.50 D difference in
 293 astigmatism between corresponding meridians in the two eyes.
 294 4. No more than 2 weeks (cumulative) of prior dichoptic treatment.
 295 5. No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other
 296 treatments allowed up to enrollment but then must be discontinued.
 297 6. Refractive correction is required (single vision lenses or contact lenses) for any of the
 298 following refractive errors based on a cycloplegic refraction completed within the last 7
 299 months:
 300 • Hypermetropia of 2.50 D or more by SE
 301 • Myopia of amblyopic eye of 0.50D or more SE
 302 • Astigmatism of 1.00D or more
 303 • Anisometropia of more than 0.50D SE
 304

NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).

- a. Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
 - SE must be within 0.50D of fully correcting the anisometropia (if new glasses are prescribed, reduction in plus sphere must be symmetric in the two eyes).
 - SE must not be under corrected by more than 1.50D SE.
 - Cylinder power in both eyes must be within 0.50D of fully correcting the astigmatism.
 - Axis must be within +/- 10 degrees if cylinder power is $\leq 1.00D$, and within +/- 5 degrees if cylinder power is $> 1.00D$.
 - Myopia must not be under corrected by more than 0.25D or over corrected by more than 0.50D SE, and any change must be symmetrical in the two eyes.
- b. Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
 - For at least 18 weeks (immediately prior to enrollment) **OR** until VA stability is documented (defined as < 0.1 logMAR change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
 - For determining VA stability (non-improvement):
 - The **first** of two measurements may be made 1) in current correction, or 2) in trial frames with or without cycloplegia or 3) without correction (if new correction is prescribed),
 - The **second** measurement must be made without cycloplegia in the correct spectacles/contact lens correction that has been worn for at least 9 weeks.
 - NOTE: Because this determination is a pre-randomization, the method of measuring VA is not mandated.
7. Participant is willing to wear the Luminopia headset.
8. Participant is willing to continue full-time spectacles/contact lens wear (if needed).
9. Participant is willing to accept assignment to either dichoptic shows (view 1 hour per day 6 days per week) OR part-time patching (2 hours per day 7 days per week) for 26 weeks.
10. Interpupillary distance of 52mm to 72mm inclusive.
11. Investigator is willing to prescribe Luminopia or patching per protocol.
12. Parent understands the protocol and is willing to accept randomization.
13. Parent has phone (or access to phone) and is willing to be contacted by JAEB Center.
14. Relocation outside area of active PEDIG site within the next 52 weeks is not anticipated.

2.4 Participant Exclusion Criteria

Individuals meeting any of the following criteria will be excluded from study participation.

1. Heterotropia more than 5Δ at distance or near (measured by SPCT in current correction)
2. Prism lenses or need of a prism prescription at enrollment.
3. Current bifocal spectacles (eligible only if bifocal discontinued 2 weeks prior to enrollment).

- 352 4. Myopia greater than -6.00D spherical equivalent in either eye.
353 5. Previous intraocular or refractive surgery.
354 6. Known skin reactions to patch or bandage adhesives.
355 7. Ocular co-morbidity that may reduce VA determined by an ocular examination
356 performed within the past 7 months (*Note: nystagmus per se does not exclude the*
357 *participant if the above visual acuity criteria are met using patch occlusion. Fogging is*
358 *not permitted*).
359 8. Diplopia more than once per week over the last week prior to enrollment by parental
360 report.
361 9. History of light-induced seizures.
362 10. Severe developmental delay that would interfere with treatment or evaluation (in the
363 opinion of the investigator). Participants with mild speech delay or reading and/or
364 learning disabilities are not excluded.
365 11. Participation in a prior study involving patching for amblyopia
366 12. Immediate family member (biological or legal guardian, child, sibling, parent) of
367 investigative site personnel directly affiliated with this study or an employee of the JAEB
368 center for Health Research.
369

370 **2.5 Procedures at Enrollment Visit**

371 **2.5.1 Historical Information**

372 After informed consent has been signed, historical information elicited will include the
373 following: date of birth, sex, race, ethnicity, history of allergy to patching, and prior amblyopia
374 therapy including refractive correction.
375
376

377 **2.5.2 Ability to Use Luminopia**

378 Interpupillary distance will be measured using investigator's standard method or a PEDIG-
379 provided IPD ruler. Participants with interpupillary distance <52mm or >72mm will not be
380 eligible to participate in the study.
381

382 Site personnel will confirm that the participant is able and willing to wear the Luminopia headset
383 by:

- 384 1. Showing the child the devices in the clinic and allowing them to try them on, if desired.
 - 385 2. Asking the child if they are willing to wear the headset for up to an hour a day, 6 days a
386 week.
- 387

388 **2.5.3 Clinical Testing**

389 Participants who meet all eligibility criteria in section 2.3 and 2.4 including visual acuity stability
390 criteria in current spectacles/contact lens correction will complete the following tests and
391 assessments.
392

393 All examination procedures must be tested on the day of enrollment, except the cycloplegic
394 refraction and ocular examination, which may be performed within 7 months prior to enrollment.
395

396 The following procedures should be performed at the enrollment visit in the following order:
397

398 **Lensometry:**

399 Verify current refractive correction by lensometry. If a participant is wearing contact lenses,
400 verify contact lens prescription.

401
402 **Questionnaires:**

- 403
404 1. Assessment of Binocular Diplopia:
405 An estimate of the frequency of diplopia (if any) will be determined by asking the parent
406 “has your child complained of double vision over the last week.” If yes, the parent is asked
407 how frequently during the last week the child has complained of double vision: “once per
408 week,” or “2 to 3 times per week,” or “4 or more times per week.” Any study personnel may
409 assess diplopia. Children who have reported diplopia more than once over the past week are
410 ineligible (see section 2.3).
411 2. PedEyeQ Functional Vision Domain⁴⁶:
412 A child questionnaire for children ages 5-7 years (inclusive), and a proxy questionnaire
413 completed by the parent regarding their child’s functional vision. The child questionnaire is
414 administered to the child by study personnel. The Proxy questionnaire is completed by the
415 parent.
416 3. PedEyeQ Social Domain and Frustration/Worry Domain⁴⁶:
417 Child questionnaire for children ages 5-7 years (inclusive), and proxy questionnaire
418 completed by the parent regarding their child. The child questionnaire is administered to the
419 child by study personnel. The Proxy questionnaire is completed by the parent.

420
421 **Clinical Testing** (in the following order) **is performed in the participant’s current refractive**
422 **correction, if required, without cycloplegia:**

- 423
424 4. Distance Visual Acuity Testing:
425 Monocular distance VA testing will be performed in current refractive correction (if
426 required) in each eye by a certified examiner using the electronic ATS-HOTV VA on a
427 study-certified VA tester displaying single surrounded optotypes.
428 5. Binocular Function Testing (by a certified examiner):
429 • Stereoacuity will be tested at 40cms in current refractive correction using the Randot
430 Preschool Test.
431 • If nil stereoacuity on the Randot Preschool Test, the Random Dot Butterfly test will
432 be performed at 40cms.
433 • If nil stereoacuity on the Random Dot Butterfly, the Worth 4-shape will be
434 administered.
435 6. Ocular Alignment Testing:
436 Ocular alignment will be assessed in current spectacle/contact lens correction by the cover
437 test, simultaneous prism and cover test (SPCT) (in cases of strabismus detected by cover
438 test), and prism and alternate cover test (PACT) in primary gaze at distance (3 meters) and at
439 near (1/3 meter).
440 7. Additional Clinical Testing:
441 Ocular examination as per investigator’s clinical routine.
442

443 **2.6 Randomization of Eligible Participants**

444 The JAEB Center will construct a Master Randomization List using a permuted block design
445 stratified by VA in the amblyopic eye as 20/40 to 20/80 (moderate impairment) versus 20/100 to
446 20/200 (severe impairment) and any previous treatment (glasses only versus other treatment in
447 addition to glasses) which will specify the order of treatment group assignments.

448
449 All eligible participants enrolled in the study will be followed for up to 52 weeks. Participants
450 will be randomly assigned in a 1:1 allocation to one of the following two treatment groups for 26
451 weeks:

- 452
- 453 • **Luminopia Group**: dichoptic movies/shows wearing the Luminopia headset prescribed
454 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day)
455 6 days a week with optical correction, if needed.
 - 456
 - 457 • **Patching Group**: patching of the fellow eye 2 hours per day (treatment time can be split
458 into shorter sessions totaling 2 hours each day) 7 days per week with optical correction, if
459 needed.

460
461 Once a child is assigned to treatment, they will be included in the analysis regardless of whether
462 the assigned treatment is received. Thus, the investigator must not randomly assign a participant
463 to treatment unless convinced that the parent will accept either of the treatments.

Chapter 3: Randomized Trial Procedures

464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504

3.1 Treatment

Investigators must not start any additional amblyopia treatment (other than that outlined below) prior to the 26-week primary outcome visit.

3.1.1 Luminopia Group

Participants randomized to the Luminopia group will be instructed to watch dichoptic movies/shows using the Luminopia device at home, for 1 hour/day, 6 days/week, for 26 weeks unless resolved at 13 weeks (see below), while continuing to wear any optical correction (including while wearing the Luminopia device).

Parents will be instructed that the 1 hour of daily treatment should be completed in a single 60-minute session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 1 hour per day. Adherence with Luminopia treatment will be recorded electronically throughout the study.

3.1.2 Patching Group

Participants assigned to the patching group will be instructed to wear an adhesive patch over the fellow eye (while continuing to wear any optical correction) for 2 hours per day, 7 days per week for 26 weeks. Parents of participants will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours per day.

Adherence with prescribed patching treatment will be monitored throughout the study using a parental calendar. Parents will be asked to complete an adherence calendar by manually recording the number of minutes that the child wore the patch each day. The investigator will review the calendars at each follow-up visit.

3.2 Phone Call

Site personnel will call all participants 1 week (7 to 13 days) after randomization to encourage adherence and confirm that there are no problems with randomized treatment. Site personnel will also call participants in the patching group who switch to Luminopia treatment at the 26-week primary outcome visit (7 to 13 days after the 26-week visit), again to encourage adherence with treatment and to confirm that there are no problems with the Luminopia device.

3.3 Follow-up Schedule Through 26-Week Primary Outcome

The follow-up schedule through 26-week primary outcome is timed from randomization:

Visit	Target Day Post-Randomization	Target Window Post-Randomization*	Allowable Window Post-Randomization
1-Week Phone Call	7 days	7 to 13 days	7 to 27 days
13-Week Office Visit	91 days	77 days to 105 days	56 days to 125 days
26-Week Primary Outcome	182 days	168 days to 196 days	126 days to 238 days

* Target window for phone calls is 7 to 13 days from previous office visit. Target window for office visits is target day +/- 2 weeks.

505 **3.3.1 Resolution of Amblyopia at 13-Week Office Visit**

506 If amblyopia resolves at the 13-week visit (defined as ≤ 0 logMAR lines IOD with fellow eye VA
507 no worse than 1 logMAR line below baseline), participants will discontinue Luminopia or
508 patching treatment but return for the 26-week primary outcome visit. No other treatment should
509 be prescribed before the 26-week outcome visit.

510
511 **3.4 Continued Follow-up Post 26-Week Primary Outcome**

512 Children originally randomized to Luminopia will end the study at 26 weeks.

513
514 Children originally randomized to Patching whose amblyopia HAS NOT resolved (1 or more
515 logMAR lines IOD is present with the originally amblyopic eye worse than fellow eye) at the 26-
516 week primary outcome visit, will be offered a trial of Luminopia treatment, and if accept
517 treatment, will continue in follow-up as defined below. Otherwise, the study will end.

518
519 The follow-up schedule through 52-week outcome is timed from the 26-week visit:
520

Visit	Target Day Post 26-week visit	Target Window Post-26-week*	Allowable Window Post-26-week
27-Week Phone Call	7 days	7 to 13 days	7 to 27 days
39-Week Office Visit	91 days	77 days to 105 days	56 days to 125 days
52-Week Office Visit	182 days	168 days to 196 days	126 days to 238 days

521
522 * Target window for phone call is 7 to 13 days from previous office visit. Target window for office visits is target
523 day +/- 2 weeks.
524

525 **3.4.1 Resolution of Amblyopia at 39-Week Office Visit**

526 If amblyopia resolves at the 39-week visit (defined as ≤ 0 logMAR lines IOD with fellow eye VA
527 no worse than 1 logMAR line below baseline), participants will discontinue treatment with
528 Luminopia, but continue follow-up until the 52-week visit.

529
530 **3.5 Follow-up Visit Testing Procedures**

531 Participants will be seen at follow-up visits as outlined in sections 3.3 and 3.4.

532
533 All procedures will be performed with the participant's current refractive correction without
534 cycloplegia.

- 535 • If a participant currently wears spectacles or contact lenses but they are not available or
536 are not within tolerance at the 13-week follow-up examination, testing may be performed
537 with current correction in trial frames.
- 538 • Habitual refractive correction (meeting study requirements) must be worn for the primary
539 outcome visit at 26 weeks.

540
541 A Masked Examiner must complete distance VA and binocular function testing at the 13, and
542 26-week visits. The masked examiner must be PEDIG certified for the required testing. All other
543 assessments are unmasked. Prior to the Masked Examiner entering the room, participants and
544 parents should be instructed not to discuss their treatment with the Masked Examiner.
545

546 The following procedures should be performed at each visit in the following order:
547

548 **Lensometry (unmasked):**

549 Verify current refractive correction by lensometry. If a participant is wearing contact lenses,
550 verify contact lens prescription.
551

552 **Questionnaires (all unmasked):**
553

554 1. Assessment of Binocular Diplopia (at 13, and 26 weeks; and at 39, and 52 weeks if treated
555 with Luminopia):

556 An estimate of the frequency of diplopia (if any) will be determined by asking the parent
557 “has your child complained of double vision over the last week.” If yes, the parent is asked
558 how frequently during the last week the child has complained of double vision: “once per
559 week,” or “2 to 3 times per week,” or “4 or more times per week.” Any study personnel may
560 assess diplopia.

561 2. Adverse Events (at 13, and 26 weeks; and at 39, and 52 weeks if treated with Luminopia):

562 A standardized questionnaire will be administered to the parent to collect data on possible
563 adverse events.

564 3. Treatment Impact Questionnaire (at 13, and 26 weeks):

565 An item bank of participant-derived questionnaire items will be completed by the child
566 themselves (for children ages 5-7 years inclusive) and by the child’s parent (proxy rating
567 regarding impact on their child and also questions regarding impact on the parent
568 themselves). Questions pertain to the impact of the child’s specific treatment on the child
569 themselves and on the parent / family.

570 4. PedEyeQ Social Domain and Frustration/Worry Domain (at 13 weeks only):

571 Child questionnaire for children ages 5-7 years (inclusive) and proxy questionnaire for the
572 parent regarding their child. The Child questionnaire is administered to the child by study
573 personnel and the Proxy questionnaire is completed by the parent.

574 5. PedEyeQ Functional Vision Domain (at 26 weeks only):

575 A child questionnaire for children ages 5-7 years (inclusive), and proxy questionnaire for the
576 parent regarding their child’s functional vision. The child questionnaire is administered to the
577 child by study personnel. The Proxy questionnaire is completed by the parent.
578

579 **Clinical Testing performed in the participant’s current refractive correction (if required)**
580 **without cycloplegia in the following order at ALL VISITS. Masked testing must be**
581 **performed by a PEDIG certified examiner.**

582 • Habitual refractive correction (meeting study criteria) is required for the 26-week
583 primary outcome exam.

584 • Testing in trial frames with current Rx is allowed at 13, 39 and 52 weeks if current
585 refractive correction is not available or does not meet study criteria.
586

587 6. Distance VA Testing (at 13, and 26 weeks masked; at 39, and 52 weeks if applicable
588 unmasked): Monocular distance VA testing will be performed in current refractive correction
589 (if required) in each eye by a certified examiner using the electronic ATS-HOTV VA on a
590 study-certified VA tester displaying single surrounded optotypes.

- 591 7. Binocular Function Testing by a certified examiner in current refractive correction if required
 592 (at 13, and 26 weeks Masked; at 39, and 52 weeks if applicable unmasked):
 593 • Stereoacuity will be tested at 40cms in current refractive correction using the Randot
 594 Preschool Test.
 595 • If nil stereoacuity on the Randot Preschool Test, the Random Dot Butterfly test will
 596 be administered at 40cms.
 597 • If nil stereoacuity on the Random Dot Butterfly, then the Worth 4-shape will be
 598 administered at 40cms.
 599 8. Ocular Alignment Testing (Unmasked): Ocular alignment will be assessed by a certified
 600 examiner in current spectacle/contact lens correction by the cover test, SPCT (in cases of
 601 strabismus detected by cover test), and PACT in primary gaze at distance (3 meters) and at
 602 near (1/3 meter).
 603 9. Adherence Monitoring (Unmasked): Adherence data Luminopia will be downloaded and
 604 patching adherence calendars will be reviewed.
 605

606 **3.5.1 Masked Examiner**

607 The Masked Examiner must be certified to test VA and binocular function testing. Because the
 608 Masked Examiner must be masked to the participant’s treatment group and be someone other
 609 than the managing clinician (in many cases the managing clinician will be the investigator, but
 610 this is not required).
 611

612 **3.6 Non-Study Visits and Treatment**

613 Investigators may schedule additional visits at their own discretion. Participants will continue to
 614 follow the study-specified follow-up schedule regardless of any non-study visits. No data will be
 615 collected at non-study visits for the purpose of the study.
 616

617 Investigators must not start any additional non-randomized amblyopia treatment or stop
 618 randomized treatment prior to the 26-week primary outcome visit without first contacting a
 619 protocol chair. As part of randomized treatment, if amblyopia is resolved at 13 weeks,
 620 randomized treatment can be discontinued.
 621

622 For participants who continue in the study after 26 weeks, Luminopia treatment may be stopped
 623 at 39 weeks if amblyopia meets resolution criteria, but otherwise Luminopia treatment will
 624 continue up to the 52-week visit. No other treatment should be prescribed prior to the 52-week
 625 outcome visit.
 626

627 **3.7 Management of Refractive Error**

628 No cycloplegic refraction is mandated during the study. Nevertheless, if the investigator suspects
 629 that refractive error may not be corrected according to study guidelines, a cycloplegic refraction
 630 should be performed. If the new cycloplegic refraction compared to the old cycloplegic
 631 refraction differs by ≥ 0.75 D sphere or ≥ 0.75 D cylinder or ≥ 0.75 D in SE anisometropia or axis
 632 change of 6 degrees or more when cylinder is 1.00 D or more; then a change in spectacles is
 633 required. Whether to update the spectacles for smaller changes in refraction is at investigator
 634 discretion.
 635

636 When new spectacles are prescribed, the refractive correction prescribed must meet the
637 requirements as described in section 2.3 #6. The updated spectacles will be paid for by the study.

638

639 **3.8 Management of Strabismus**

640 Because of the short duration of the primary outcome for the study and the age group being
641 studied, strabismus surgery is not allowed prior to the 26-week primary outcome visit.

642

643 If surgery must be performed, a protocol chair should be contacted and a masked exam prior to
644 surgery scheduled. The participant should remain in the study and complete all necessary visits.

645 If surgery is performed, it must be recorded in the comment section of the Follow-up
646 Examination Form.

Chapter 4: Study Device

647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690

4.1 Description of the Luminopia Device

Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. The software application requires an internet connection for treatment. The Luminopia medical software application presents slightly different video content to each eye to encourage amblyopic eye usage. Treatment using Luminopia will be prescribed for 1 hour per day, 6 days per week, consistent with its FDA approval.

4.1.1 Headset

The study will provide each participant with a VR headset pre-loaded with Luminopia software. The VR headset has a screen resolution of 564 pixels per inch, which constitutes the minimum display resolution requirement. The Luminopia system has been approved by the FDA for the treatment of moderate or severe amblyopia in children 4 to 7 years of age.

The Luminopia device should only be used in accordance with the manufacturer's instructions. Use in a safe and stationary environment with the HMD connected to Wi-Fi. Luminopia should only be used with the participant seated or lying down. If the participant experiences discomfort because the Luminopia device feels too heavy, the participant should try to use the Luminopia device while lying down on their back.

The HMD should be kept away from heat sources, water, moisture, open flames, or direct sunlight. If the participant intends to use the Luminopia device away from home for an extended period of time, the parent should bring the charger provided with the HMD to charge the device as needed. The participant should not use the Luminopia device while the HMD is charging.

4.1.2 Internet Requirements

Wireless internet with Wi-Fi speed near the router that exceeds 5 Mbs is required to operate Luminopia. Faster network speeds will result in a better product experience. Potential study participants who do not have the required internet capabilities in their home will be provided Wi-Fi access using a Hotspot at no cost for the duration of the study.

4.2 Device Delivery and Return

Device Delivery and Return procedures will be detailed in the site instruction manual.

4.3 Device Accountability Procedures

Device accountability procedures will be detailed in the site instruction manual.

4.3.1 Device Failure

Parents will be provided with written instructions regarding the process to follow should the Luminopia device fail. If the device needs to be replaced PEDIG will provision a replacement.

691 **4.3.2 Participant Access to Study Device After Primary Outcome Visit**

692 Participants randomly assigned to receive patching treatment who have not resolved at the 26-
693 week primary outcome visit, will be offered Luminopia therapy and if accepted, followed
694 forward with a 27-week phone call and follow-up visits at 39-weeks and 52-weeks post-
695 randomization. Luminopia therapy will NOT continue beyond the 52-week visit.

696

697 Participants randomly assigned to receive Luminopia will end treatment after the 26-week
698 primary outcome visit.

699

Chapter 5: Testing Procedures and Questionnaires

700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744

5.1 Questionnaires

1. Assessment of Binocular Diplopia:

An estimate of the frequency of diplopia (if any) will be determined by asking the parent “has your child has complained of double vision over the last week.” If yes, the parent is asked how frequently during the last week the child has complained of double vision: “once per week,” or “2 to 3 times per week,” or “4 or more times per week.” Any study personnel may ask the parent to rate diplopia. Testing time is approximately 1 minute.

2. PedEyeQ Functional Vision Domain:

A child questionnaire for children ages 5-7 years (inclusive) and a proxy questionnaire completed by the parent regarding their child’s functional vision. The child questionnaire is administered by study personnel. The proxy questionnaire is completed by the parent. The questionnaires take about 3-4 minutes to complete.

3. PedEyeQ Social Domain:

A child questionnaire for children ages 5-7 years (inclusive) and a proxy questionnaire completed by the parent regarding their child’s social concerns. The child questionnaire is administered by study personnel. The Proxy questionnaire is completed by the parent. The questionnaires take about 3-4 minutes to complete.

4. PedEyeQ Frustration / Worry Domain:

A child questionnaire for children ages 5-7 years (inclusive), a proxy questionnaire completed by the parent regarding their child’s Frustration / Worry. The child questionnaire is administered by study personnel. The Proxy questionnaire is completed by the parent. The questionnaires take about 3-4 minutes to complete.

5. Treatment Impact Questionnaire:

An item bank of participant-derived questionnaire items will be completed by the child themselves (for children ages 5-7 years inclusive) and by the child’s parent (proxy rating regarding impact on their child and also questions regarding impact on the parent themselves). Questions pertain to the impact of the child’s specific treatment on the child themselves and on the parent / family. Testing is anticipated to take 5-7 minutes.

6. Adverse Event Questionnaire:

A standardized questionnaire will be administered to the parent to collect data on possible adverse events. The questionnaire is anticipated to take 1 minute to complete.

5.2 Clinical Assessments

The following procedures will be performed at each visit as defined in the *ATS Procedures Manual*:

7. Distance VA Testing:

745 Monocular distance VA testing will be performed in refractive correction in each eye by a
746 certified examiner using the electronic ATS-HOTV VA protocol on a study-certified VA
747 tester displaying single surrounded optotypes. The VA protocol used at enrollment will be
748 used throughout the study regardless of age at follow-up. Testing time for both eyes typically
749 is in the range of 5 to 15 minutes.

750

751 8. Binocular Function Testing (by a certified examiner):

752 Stereoacuity will be tested at 40cms in current refractive correction using the Randot
753 Preschool Test.

754 • If nil stereoacuity on the Randot Preschool Test, then the Random Dot Butterfly test
755 will be administered at 40 cm.

756 • If nil stereoacuity on the Random Dot Butterfly, the hand-held Worth 4-Shape test
757 will be performed at 40 cm.

758 • Testing typically takes 3-5 minutes.

759

760 9. Ocular Alignment Testing: Ocular alignment will be assessed by a certified examiner in
761 current spectacle correction by the cover test, simultaneous prism and cover test (SPCT) (in
762 cases of strabismus detected by cover test), and prism and alternate cover test (PACT) in
763 primary gaze at distance (3 meters) and at near (1/3 meter). Testing time is typically 1 to 3
764 minutes.

765

Chapter 6: Miscellaneous Considerations

766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801

6.1 Contacts by the Jaeb Center for Health Research and Sites

The Jaeb Center serves as the PEDIG Coordinating Center. The Jaeb Center will be provided the parents' contact information. The Jaeb Center may contact the parents of the participants. Permission for such contacts will be included in the Informed Consent Form. The principal purpose of the contacts will be to develop and maintain rapport with the participant's family and to help coordinate the scheduling of study visits, when needed.

6.2 Participant Compensation

Participant compensation will be specified in the informed consent form.

6.3 Cost of Treatment

Any new or changes to optical correction will be paid for during the study.

For those randomized to patching, patches will be paid for by the study for 26-weeks.

For those randomized to Luminopia, the cost of prescribed dichoptic treatment for 26-weeks will be paid for by the study.

For those randomized to patching who have residual amblyopia at 26 weeks, the cost of dichoptic treatment with Luminopia, if accepted, through 52-weeks will be paid for by the study.

For those randomized to Luminopia, the study will not pay for continued Luminopia treatment outside the study.

6.4 Participant Withdrawal

Participation in the study is voluntary and a participant may withdraw at any time. For participants who withdraw, their data collected prior to their withdrawal will be used. This stipulation is specified in the consent form.

6.5 Confidentiality

For security and confidentiality purposes, participants will be assigned an identifier that will be used instead of their name. Protected health information gathered for this study will be shared with the coordinating center, the Jaeb Center for Health Research in Tampa, FL. De-identified participant information may also be provided to research sites involved in the study.

802 **Chapter 7: Unanticipated Problem and Adverse Event Reporting**

803

804 **7.1 Unanticipated Problems**

805 Site investigators will promptly report to the Coordinating Center on an eCRF all unanticipated
806 problems meeting the criteria below. Sites must report Unanticipated Problems to the IRB within
807 seven (7) calendar days of recognition. For this protocol, an unanticipated problem is an incident,
808 experience, or outcome that meets all three (3) of the following criteria:

809

- 810 1. Is unexpected (in terms of nature, severity, or frequency) given (a) the research
811 procedures that are described in the protocol-related documents, such as the IRB-
812 approved research protocol and informed consent document and (b) the characteristics of
813 the participant population being studied
- 814 2. Is related or possibly related to participation in the research (possibly related means
815 there is a reasonable possibility that the incident, experience, or outcome may have been
816 caused by the procedures involved in the research)
- 817 3. Suggests that the research places participants or others at a greater risk of harm than was
818 previously known or recognized (including physical, psychological, economic, or social
819 harm)

820

821 The Coordinating Center also will report to the IRB all unanticipated problems not directly
822 involving a specific site such as unanticipated problems that occur at the Coordinating Center.
823 These instances must be reported to the JCHR IRB within seven (7) calendar days of recognition.
824 The Director of the Human Research Protection Program will report to the appropriate regulatory
825 authorities if the IRB determines that the event indeed meets the criteria of an Unanticipated
826 Problem that requires further reporting.

827

828 **7.2 Adverse Events**

829

830 **7.2.1 Reportable Adverse Events**

831 Because study treatment with patching and Luminopia are non-invasive and consistent with
832 usual clinical care, it is not expected that there would be significant adverse events other than
833 those already being captured as part of the clinical outcome assessments or questionnaire (e.g.,
834 worsening of fellow eye VA, development of new or worsening of strabismus, new diplopia, or
835 report of headache, eyestrain, nausea, seizures, dizziness, increase in frequency of night terrors,
836 or skin irritation).

837

838 **7.2.2 Safety Oversight**

839 A Data and Safety Monitoring Committee (DSMC) will review compiled safety data at periodic
840 intervals, with a frequency of no less than twice a year. The DSMC can request modifications to
841 the study protocol or suspension or outright stoppage of the study if deemed necessary based on
842 the totality of safety data available. Details regarding DSMC review will be documented in a
843 separate DSMC charter.

844

845 The objective of the DSMC review is to decide whether the study (or study treatment for an
846 individual or study cohort) should continue per protocol, proceed with caution, be further
847 investigated, be discontinued, or be modified and then proceed. Suspension of enrollment (for a

848 particular group, a particular study site, or for the entire study) is a potential outcome of a DSMC
849 safety review.

850

851 **7.2.3 Stopping Criteria**

852 The study may be discontinued by the Steering Committee (with approval of DSMC) prior to the
853 preplanned completion of follow-up for all study participants. No formal guidelines for stopping
854 the study for futility or efficacy are pre-specified (see section 7).

855

856 **7.2.4 Participant Discontinuation of Study Treatment**

857 Rules for discontinuing study treatment use are one of the following:

858

- 859 • The investigator believes it is unsafe for the participant to continue to receive the
860 treatment.
- 861 • The participant or parent requests that the treatment be stopped.

862

863 Even if the study treatment is discontinued, the participant will be encouraged to remain in the
864 study through the 26-week Primary Outcome Visit with permission from the parent to allow
865 ongoing data collection.

866

Chapter 8: Statistical Considerations

8.1 Statistical and Analytical Plans

The approach to sample size and statistical analyses are summarized below.

868

869

8.2 Study Objective and Statistical Hypothesis

870

871

8.2.1 Primary Efficacy Outcome

The primary objective of the study is to determine if treatment by watching dichoptic movies/shows wearing the Luminopia One headset (subsequently referred to as LUMINOPIA) is non-inferior to treatment with 2 hours of patching per day 7 days per week (subsequently referred to as PATCHING) with respect to change in amblyopic eye distance VA from randomization to 26 weeks.

878

The primary efficacy outcome will be the change in amblyopic eye distance VA (measured as logMAR) from randomization to 26 weeks. Change in logMAR will be calculated as [outcome VA] – [randomization VA] such that a negative change indicates improvement in visual acuity, and a positive change indicates worsening.

883

The study is designed to test a one-sided null hypothesis that LUMINOPIA is inferior to PATCHING by 0.0625 logMAR (i.e., 5/8 of one line) or more in favor of the alternative hypothesis that LUMINOPIA is non-inferior to PATCHING.

886

887

$H_0: \mu_{\text{PATCHING}} - \mu_{\text{LUMINOPIA}} \leq -0.0625 \text{ logMAR}$ (LUMINOPIA inferior to PATCHING)

888

889

$H_a: \mu_{\text{PATCHING}} - \mu_{\text{LUMINOPIA}} > -0.0625 \text{ logMAR}$ (LUMINOPIA not inferior to PATCHING)

890

To represent the difference between treatment groups (PATCHING minus LUMINOPIA), a two-sided 95% confidence interval (CI) will be constructed. Since the LOWER limit of a two-sided 95% CI is equivalent to the LOWER limit of a one-sided 97.5% CI, this will allocate a significance level of 0.025 to be used in testing noninferiority.

895

Non-inferiority of LUMINOPIA to PATCHING will be declared if the LOWER limit of the two-sided 95% CI for the difference between treatment groups is greater than the non-inferiority limit of -0.0625 logMAR favoring PATCHING (Figure 1).

898


899

If non-inferiority is declared, a test of no difference (superiority test) for LUMINOPIA compared

901

902

903 **Figure 1. Depiction of Null and Alternative Hypotheses for Treatment Group Difference**
 904 Mean difference (PATCHING – LUMINOPIA) and 95% CI of amblyopic eye distance VA



905
 906
 907
 908

8.3 Sample Size

909 **8.3.1 Effect of PATCHING**

910 To estimate the treatment effect for those randomized to PATCHING, visual acuity data from
 911 participants prescribed 2 hours daily patching in a previous PEDIG study, ATS18,³¹ were used.
 912 The data were limited to participants who met the eligibility criteria for the current study. In
 913 ATS18, 75 participants between the ages of 5 to 7 years experienced 0.17 logMAR (95% CI:
 914 0.14 to 0.20) mean improvement in visual acuity after 16 weeks with a standard deviation of 0.13
 915 logMAR (95% CI: 0.12 to 0.16).

916 **8.3.2 Effect of LUMINOPIA**

917 To estimate the treatment effect for those randomized to LUMINOPIA, visual acuity data from
 918 participants randomized to LUMINOPIA therapy were reviewed. Xiao et al³⁶ conducted a
 919 randomized trial comparing dichoptic movies using the Luminopia device versus continued
 920 glasses alone. Of 103 enrolled children (aged 4 to 7 years) 52 were randomly assigned to
 921 continued glasses and 51 to dichoptic movies using Luminopia 1 hour/day, 6 days a week. At the
 922 12-week outcome, mean amblyopic eye VA had improved 0.18 logMAR (95% CI: 0.14 to 0.23;
 923 n=45) in the Luminopia group and 0.08 logMAR (95% CI: 0.04 to 0.13; n=45) in the continued
 924 glasses group. The study was stopped early for success having a difference between groups of
 925 1.0 lines; P = 0.0011; 96.14% CI, 0.33-1.63 lines).

926
 927 In a preceding non-randomized study,³⁸ Xiao et al prescribed Luminopia 1 hour/day for 12
 928 weeks to 90 children 4- to 12-years of age (mean 6.7 ± 2.0 years) with amblyopia. Overall
 929 (n=74) the mean amblyopic-eye VA improved 0.15 logMAR (95% CI: 0.12 to 0.18) after 12
 930 weeks.³⁸

931

932 **8.3.3 Selection of Noninferiority Margin**

933 The non-inferiority (NI) margin for the primary outcome was determined by the Planning
 934 Committee using clinical judgment; based on simulated distributions of VA improvement
 935 corresponding to a mean difference between 2 populations of 0.025, 0.050, 0.0625, 0.075 and
 936 0.10 logMAR. Side-by-side histograms illustrating the shift in the distribution for each mean
 937 were reviewed along with corresponding differences in proportions for clinically meaningful cut
 938 points, e.g., difference in percent improving by 0.2 logMAR or more (2 or more logMAR lines),
 939 or percent with final VA of 20/32 (0.2 logMAR) or better.

940
 941 The consensus of the Planning Committee was that if LUMINOPIA was no worse than
 942 PATCHING by 0.0625 logMAR then LUMINOPIA would be considered non-inferior to
 943 PATCHING. This mean difference corresponded to a difference of 16% improving 2 or more
 944 logMAR lines (59% in the PATCHING group and 43% in the LUMINOPIA group).

945
 946 As an alternative approach, the NI margin was calculated using statistical criteria, using half the
 947 lower limit of the 95% CI for change in VA after patching treatment in ATS18 as a guideline. In
 948 ATS18, half the lower limit of the 95% CI for change after 16 weeks was 0.07 logMAR;
 949 therefore, 0.0625 logMAR is a conservative choice as a noninferiority (NI) margin.

951 **8.3.4 Sample Size Calculations and Assumptions**

952 A common standard deviation (SD) of 0.14 logMAR and a true mean difference of 0.00 logMAR
 953 between LUMINOPIA and PATCHING groups were selected to calculate the required sample
 954 size for the current study. With the between-group difference of the change in logMAR VA
 955 calculated as PATCHING minus LUMINOPIA, the noninferiority margin would be -0.0625
 956 logMAR to show directionality of the primary outcome hypotheses (Figure 1, section 8.2.1).

957
 958 Using a noninferiority margin of -0.0625 logMAR and a one-sided Type 1 error rate of 0.025,
 959 the study would require 214 participants total (107 participants in each treatment arm) to
 960 complete the primary outcome to achieve 90% power to reject the null hypothesis that
 961 LUMINOPIA is not non-inferior to PATCHING (Table 1). With an anticipated 10% loss to
 962 follow up, the adjusted sample size to enroll is 238 total (214 ÷ 0.90).

963
 964 **Table 1. Total Sample Size Estimates***

SD of Change in VA (logMAR)	True Treatment Group Difference in Mean logMAR VA Change at 26-weeks [PATCHING – LUMINOPIA]				
	-0.025 Favoring PATCHING	-0.0125 Favoring PATCHING	0 No Difference	0.0125 Favoring LUMINOPIA	0.025 Favoring LUMINOPIA
0.13	508	288	184	130	96
0.14	588	332	214	150	110
0.15	676	382	246	172	126

965 *Cells reflect total sample size unadjusted for loss to follow up with NI -0.0625 logMAR, one-
 966 sided alpha of 0.025, and 90% power.

967

968 Positive values for the true difference indicate greater VA improvement with LUMINOPIA
 969 treatment as compared to PATCHING treatment. Negative values for the true difference indicate
 970 greater VA improvement with PATCHING than LUMINOPIA (Figure 1, Table 1).
 971

972 **8.3.5 Power for Superiority**

973 If non-inferiority is declared, a two-sided test of no difference (superiority test) for LUMINOPIA
 974 compared with PATCHING will be conducted. Superiority of LUMINOPIA over PATCHING
 975 will be declared if the LOWER limit of the 95% CI is greater than zero. Conversely, superiority
 976 of PATCHING over LUMINOPIA will be declared if the UPPER limit of the 95% CI is less
 977 than zero; in this scenario, LUMINOPIA would be both inferior to PATCHING and non-inferior
 978 to PATCHING with a margin of -0.0625 logMAR distance VA (Figure 1).
 979

980 Table 2 below shows the projected statistical power to reject a null hypothesis of no difference in
 981 favor of an alternative hypothesis that the treatment groups differ for various true differences and
 982 standard deviations with a two-sided alpha of 0.05 and a sample size of 214 participants
 983 completing the primary outcome.
 984

985 If 214 participants complete the primary outcome, the study has 90% power to reject a null
 986 hypothesis of no difference in favor of an alternative hypothesis that the treatment groups differ
 987 if the true difference is as small as 0.0625 logMAR, assuming SD = 0.14 with a two-sided alpha
 988 of 0.05.
 989

990 **Table 2. Power for Testing Superiority of Mean Change in VA (two-sided $\alpha=0.05$, N=214)**
 991

	True Difference 0.050 logMAR	True Difference 0.0625 logMAR	True Difference 0.075 logMAR
SD	Power	Power	Power
0.12	85%	96%	99%
0.13	80%	93%	98%
0.14	73%	90%	97%
0.15	68%	85%	95%
0.16	62%	81%	92%

992
 993 **8.4 Outcome Measures**

994 *Primary Efficacy Endpoint:*

- 995 • Change in amblyopic eye distance VA from baseline at 26 weeks.

996
 997 *Secondary Efficacy Endpoints:*

- 998 • Change in child and proxy PedEyeQ Functional Vision domain scores from baseline at
 999 26 weeks.
- 1000 • Change in child and proxy PedEyeQ Social domain scores from baseline at 13 weeks.
- 1001 • Change in child and proxy PedEyeQ Frustration/Worry domain scores from baseline at
 1002 13 weeks.

1004 *Exploratory Efficacy Endpoints:*

- 1005 • Change in amblyopic eye distance VA from baseline at 13 weeks.
- 1006 • Change in amblyopic eye distance VA over 26 weeks (area under the curve).
- 1007 • Improvement of amblyopic eye distance VA by 2 or more lines (0.2 logMAR) at 13 and
- 1008 26 weeks, respectively.
- 1009 • Resolution of amblyopia at 13 and 26 weeks, respectively as defined in section 3.3.1 and
- 1010 3.4.1.
- 1011 • Change in binocular function score from baseline at 13 and 26 weeks.
- 1012 • Child, proxy, and parent Treatment Impact Questionnaire scores at 13 weeks and 26
- 1013 weeks.

1014

1015 **8.5 Analysis Datasets and Sensitivity Analyses**

1016 Analyses will follow the intent-to-treat principle (ITT); all participants will be analyzed

1017 according to their randomized treatment group, irrespective of adherence or compliance.

1018 However, a per protocol analysis will be performed for the primary outcome to check sensitivity

1019 of the results (details to be outlined in the statistical analysis plan [SAP]). The intent-to-treat

1020 analysis is considered primary and if the results of the per-protocol analysis and intent-to-treat

1021 give inconsistent results, exploratory analyses will be performed to evaluate possible factors

1022 contributing to the differences.

1023

1024 **8.6 Analysis of the Primary Efficacy Outcome**

1025 The primary outcome, change in amblyopic eye logMAR distance VA from baseline at 26

1026 weeks, is a continuous outcome that will be analyzed using an analysis of covariance

1027 (ANCOVA) model to estimate the adjusted mean difference between PATCHING and

1028 LUMINOPIA. The model will adjust for baseline amblyopic-eye distance VA and prior

1029 treatment for amblyopia (glasses only vs other treatment in addition to glasses). The adjusted

1030 between-group mean difference and two-sided 95% confidence interval will be reported. If an

1031 imbalance of factors between treatment groups is observed, a sensitivity analysis may be

1032 performed, controlling for these potential confounders.

1033

1034 Non-inferiority of LUMINOPIA compared to PATCHING will be declared if the LOWER limit

1035 of the two-sided 95% CI for the difference between treatment groups in mean change in logMAR

1036 distance VA from baseline to 26 weeks (PATCHING minus LUMINOPIA) is greater than the

1037 non-inferiority limit of -0.0625 logMAR favoring PATCHING. Note that the LOWER limit of a

1038 two-sided 95% confidence interval is equivalent to the lower limit of a one-sided 97.5%

1039 confidence interval.

1040

1041 If non-inferiority is declared, superiority of LUMINOPIA over PATCHING will be declared if

1042 the LOWER limit of the 95% CI is greater than zero. Conversely, superiority of PATCHING

1043 over LUMINOPIA will be declared if the UPPER limit of the 95% CI is less than zero; in this

1044 scenario, LUMINOPIA would be both inferior to PATCHING and non-inferior to PATCHING

1045 with a margin of 0.0625 logMAR distance VA (Figure 1).

1046

1047 Participants who do not complete the 26-week visit will have their 26-week amblyopic eye

1048 distance VA imputed. Markov chain Monte Carlo multiple imputation with 100 imputations will

1049 be used to impute missing data; variables in the imputation model will include prior treatment for

1050 amblyopia and amblyopic-eye VA at baseline, 13, and 26 weeks. Imputation will be carried out
 1051 separately for PATCHING and LUMINOPIA.⁴⁷ Reasons for which a participant may not
 1052 complete the 26-week visit are outlined in section 7.13, “Intercurrent Events.”

1053
 1054 The ANCOVA model assumptions of linearity, normality, and homoscedasticity (equal variance)
 1055 will be verified with graphical methods. If assumptions are seriously violated, then
 1056 transformation of dependent or independent variables, elimination or categorization of
 1057 continuous covariates, a robust method, or a nonparametric method may be considered.
 1058

1059 As a sensitivity analysis, the primary outcome will be analyzed using complete cases rather than
 1060 the imputed data. If the results from these analyses are discordant, then differences between
 1061 participants with and without complete visit data will be evaluated. Additional sensitivity
 1062 analyses will be detailed in the SAP.
 1063

1064 **8.7 Analysis of the Secondary Efficacy Outcomes**

1065 Secondary analyses will test the null hypothesis of no difference between treatment groups. Both
 1066 *p*-values and confidence intervals will be reported with adjustments for multiplicity (described in
 1067 section 8.15).
 1068

1069 **8.7.1 Pediatric Eye Disease Questionnaire (PedEyeQ)**

1070 Quality of life will be evaluated for children respondents aged 5 to 7 years in each treatment
 1071 group using the PedEyeQ questionnaire. Additionally, the parent will answer on behalf of his/her
 1072 child as a proxy for children 4 to 7 years of age. Scores on Functional Vision, Frustration/Worry,
 1073 and Social domains will be assessed for both child and proxy at baseline as well as at the visit
 1074 week indicated below (Table 3). Responses will be Rasch scored according to reference tables
 1075 and standardized on a ratio scale ranging from 0 to 100.⁴⁶
 1076
 1077

Table 3. Structure of the PedEyeQ Analysis: Domains and Respondents

Participant Age	Respondent Level	Domain			Outcomes
		Social (13 weeks)	Frustration/Worry (13 weeks)	Functional Vision (26 weeks)	
4-7 years	Proxy	1	1	1	3
5-7 years	Child	1	1	1	3

Total = 6

1078 Univariate analysis of covariance (ANCOVA) will be used to assess the difference between
 1079 treatment groups across all domains and respondents (3 domains × 2 respondents = 6 outcomes)
 1080 as shown in Table 3. Models will be adjusted for prior treatment for amblyopia and enrollment
 1081 scores. The treatment effect will be summarized as a mean difference and 95% confidence
 1082 interval. Similar to the primary outcome, missing data will be imputed using multiple imputation
 1083 with prior treatment for amblyopia and baseline and outcome scores included in the imputation
 1084 model and stratified by treatment group.
 1085

1086 **8.8 Intervention Adherence**

1087 At 13, and 26-weeks, the investigator will assess participant adherence to the assigned treatment.
 1088 For each participant randomized to LUMINOPIA, the number of dichoptic treatment hours will
 1089 be categorized according to percentage of prescribed treatment time as 75-100%, 50-75%, or

1090 <50%. PATCHING calendar data will not be analyzed other than a subjective assessment by the
 1091 investigator of adherence at 13, and 26-weeks as Excellent, Good, Fair, or Poor after review of
 1092 calendar and interview with parent. The tabulation of data related to treatment adherence is
 1093 intended for exploratory purposes only, and therefore formal comparisons between treatment
 1094 groups will not be performed.

1095 **8.9 Protocol Adherence and Retention**

1096 Protocol deviations and visit completion rates (excluding participants who die before the end of
 1097 the visit window) will be tabulated for each treatment group.

1098
 1099 **8.10 Intercurrent Events**

1100 If any of the following events take place before the 26-week outcome, missing follow-up data
 1101 will be imputed for the participant experiencing the event in the primary ITT analysis.

- 1102 • Death
- 1103 • Lost to follow up
- 1104 • Withdrawal

1105
 1106 If any of the following events occur before the 26-week outcome, data will not be imputed for
 1107 participants experiencing these events, since the event itself does not preclude completion of
 1108 study visits. Thus, the observed data at the 26-week outcome visit will be utilized.

- 1109 • Treatment discontinuation
- 1110 • Treatment crossover
- 1111 • Receipt of non-protocol treatment

1112
 1113 **8.11 Safety Analyses**

1114 The cumulative proportions of each of the following adverse events by treatment group will be
 1115 assessed at the initial study phase (enrollment to 26 weeks) and during the LUMINOPIA
 1116 treatment phase for those originally randomized to PATCHING (26 weeks to 52 weeks). During
 1117 the initial study phase, the proportions will be compared statistically with Barnard's
 1118 Unconditional Exact Test considering the number of participants per group as fixed. As type II
 1119 error (false negative) is more of a concern than type I error (false positive) in safety analyses, we
 1120 will use $p \leq 0.05$, without adjustment for multiplicity, to define statistical significance in all
 1121 safety analyses. It is noted that this study is not powered for safety analyses and that absence of a
 1122 significant effect cannot be taken as evidence that a difference does not exist. The proportion of
 1123 adverse events occurring during the LUMINOPIA treatment phase for original PATCHING
 1124 participants will be tabulated.

- 1125
- 1126 • Worsening of best-corrected fellow-eye distance VA of 0.2 logMAR or more
- 1127 • New onset strabismus $>5 \Delta$ by SPCT in participants with no strabismus at baseline
- 1128 • Strabismus $>10 \Delta$ by SPCT in participants with strabismus at baseline
- 1129 • Parental report of diplopia occurring more than once per week
- 1130 • Skin irritation
- 1131 • Headache
- 1132 • Seizures
- 1133 • Eyestrain
- 1134 • Dizziness

- 1135 • Night terrors
- 1136 • Eye twitching
- 1137 • Facial redness

1138
 1139 The PEDIG DSMC will review safety data tabulated by treatment group at each of its semi-
 1140 annual meetings and can request formal statistical comparison of any safety outcome at any time
 1141 if they have cause for concern.

1142
 1143 **8.12 Baseline Descriptive Statistics**

1144 Baseline demographic and clinical characteristics will be tabulated by randomized treatment
 1145 group, and summary statistics appropriate to their distributions will be reported.

1146
 1147 **8.13 Planned Interim Analyses**

1148 There is no plan for formal interim analyses. The Data and Safety Monitoring Committee will
 1149 review tabulated and graphical displays of interim safety data at approximately 6-month intervals
 1150 and will have the option to recommend stopping the study.

1151
 1152 **8.14 Subgroup Analyses**

1153 Subgroup analyses, i.e., assessments of effect modification, will be conducted for the primary
 1154 outcome. These analyses will be considered exploratory. Missing data will be imputed like the
 1155 primary analyses except that the subgroup factors of interest, specified below, will be included in
 1156 the imputation model, which will be stratified by treatment group. Within-subgroup mean
 1157 differences for the treatment effects with 95% confidence intervals will be estimated for each
 1158 subgroup by adding an interaction term to the primary analysis models. Results will be presented
 1159 as forest plots; *p*-values will not be presented.

1160
 1161 The baseline factors to be evaluated in pre-planned exploratory subgroup analyses include
 1162 amblyopic-eye distance VA (categorized), type of amblyopia, prior treatment for amblyopia, age
 1163 4 to 5 or >5 to 7), and binocularity. The SAP will provide specific details on categorizations. The
 1164 subgroup analysis by amblyopic-eye distance VA is considered of greatest interest.

1165
 1166 There are no data to suggest that the treatment effect will vary by sex, race, or ethnicity.
 1167 However, each of these factors will be evaluated in exploratory subgroup analyses as mandated
 1168 by National Institutes of Health (NIH) guidelines.

1169
 1170 **8.15 Multiple Comparison/Multiplicity**

1171 For the primary outcome, a 95% confidence interval for the treatment group difference will be
 1172 constructed and used to evaluate the primary hypothesis of non-inferiority and also the
 1173 possibility of superiority or inferiority (Figure 1).⁴⁸

1174
 1175 For the PedEyeQ questionnaire secondary outcomes, the adaptive false discovery rate (FDR)
 1176 method with two-stage testing will control the FDR at 5% to adjust *p*-values and CIs for
 1177 multiplicity.⁴⁹

1178

1179 **8.16 Exploratory Analyses**

1180 Exploratory analyses will test the null hypothesis of no difference between treatment groups.
1181 Both *p*-values and confidence intervals will be reported without adjustment for multiplicity.

1182

1183 **8.16.1 Mean Change in Distance VA at 13 Weeks**

1184 Change in amblyopic eye VA from baseline to 13 weeks is a continuous outcome. Analyses,
1185 including imputation of missing data, will mirror the primary outcome.

1186

1187 **8.16.2 Mean Change in Distance VA over 26 weeks (area under the curve)**

1188 The change in amblyopic eye distance VA from baseline over 26 weeks (area under the curve)
1189 will be calculated for each participant using the trapezoidal rule. The analysis, including
1190 imputation of missing data, will mirror the primary outcome.

1191

1192 **8.16.3 Improvement of Amblyopic-eye Distance VA by 2 or More Lines**

1193 Improvement of amblyopic-eye distance VA of 2 or more lines (reduction of 0.2 logMAR) at 13
1194 and 26 weeks, respectively, will be analyzed as binary outcomes. For each time point, the
1195 proportions with improvement ≥ 2 lines and 95% confidence interval will be calculated. The risk
1196 difference will be calculated using logistic regression with conditional standardization and
1197 adjusted for amblyopic-eye VA at baseline and prior treatment of amblyopia. The delta method
1198 will be implemented to construct a 95% CI on the risk difference and the model-based two-sided
1199 *p*-value will be reported. Missing data will be imputed as described for the primary outcome.

1200

1201 **8.16.4 Binocular Function**

1202 The change in binocular function score from enrollment to the 13- and 26-week visit is an
1203 ordinal outcome. Components of binocularity include results from the following 3 tests: Randot
1204 Preschool Stereoacuity (RPS), Random Dot Butterfly, and Preschool Worth 4-shape (W4S) at
1205 near. These tests will create a composite ordinal score of binocularity with 9 levels.⁵¹

1206

1207 The difference between LUMINOPIA and PATCHING for the change in binocularity from
1208 baseline to 13 and 26 weeks will be evaluated with the nonparametric Wilcoxon Rank-Sum test.
1209 The difference between groups will be estimated using the Hodges-Lehmann estimator with 95%
1210 CI. Analyses for binocular function score will be limited to complete case data at each respective
1211 outcome visit (13 weeks or 26 weeks).

1212

1213 In a sensitivity analysis, binocular function scores will be analyzed using ANCOVA with
1214 adjustment for prior treatment for amblyopia and baseline binocular function score and
1215 imputation of missing data. The baseline-adjusted mean difference and 95% CI in binocularity
1216 between the treatment groups will be presented.

1217

1218 **8.16.5 Resolution of Amblyopia at 13 weeks and 26 weeks**

1219 The cumulative probability of amblyopia resolution at 13 and 26 weeks will be calculated using
1220 Cox proportional hazards regression with adjustment for baseline IOD and prior treatment for
1221 amblyopia. For each visit, the rate of resolution (estimated using the survivor function) and 95%
1222 CI will be presented for each group using direct adjustment along with the difference in rates,
1223 95% CI, and *p*-value (based on a Z test). Participants who are lost to follow up will be censored
1224 on the day of the last completed visit.

1225 **8.16.6 Treatment Impact Questionnaire**

1226 The Treatment Impact Questionnaire (TIQ) will be used as a quantitative measure to evaluate
1227 opinions regarding the burdens and impact of the randomized treatment at 13 weeks and 26
1228 weeks (as questions for the child – the Child TIQ, for the parent about the child – the Proxy TIQ,
1229 and the parent themselves – the Parent TIQ.

1230
1231 The Child-TIQ, Proxy-TIQ, and Parent-TIQ will undergo separate factor analysis to determine
1232 the number of domains for each TIQ. Each domain will be refined through the evaluation of
1233 misfitting items and will then be Rasch scored.

1234
1235 Note that because the TIQ is not administered at baseline (because treatment has not been
1236 started), there will be no adjustment for baseline score in any analysis.

1237
1238 Additional methods to score and analyze the Treatment Impact Questionnaire will be detailed in
1239 a separate SAP.

1240

1241 **8.16.7 Improvement with Dichoptic Therapy after PATCHING**

1242 Participants who were randomized to PATCHING who have 1 line or more IOD residual
1243 amblyopia will be offered dichoptic treatment with LUMINOPIA after 26 weeks. These
1244 participants will have visits at 39 weeks and 52 weeks to evaluate safety and efficacy. The same
1245 safety, binocular function, and VA outcomes evaluated at 13 and 26 weeks will be evaluated at
1246 39 and 52 weeks with 26 weeks considered the baseline visit for the extended follow-up.

Chapter 9: Data Collection and Monitoring

1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291

9.1 Case Report Forms and Other Data Collection

The main study data are collected on electronic case report forms (CRFs). When data are directly collected in real-time in electronic case report forms, this will be considered the source data. For any data points for which the eCRF is not considered source (e.g., lab results that are transcribed from a printed report into the eCRF; data not entered in real-time; etc.), the original source documentation must be maintained in the participant's study chart or medical record. This source must be readily verifiable against the values entered into eCRF. Even where all study data are directly entered into the eCRFs at office visits, evidence of interaction with a live participant must be recorded (e.g., office note, visit record, etc.)

Electronic device data files are obtained from the study software and individual hardware components. These electronic device files are considered the primary source documentation. Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH E6 and regulatory and institutional requirements for the protection of confidentiality of participants.

9.2 Study Records Retention

Study documents should be retained for a minimum of 3 years after completion of the final grant reporting. These documents should be retained for a longer period, however, if required by local regulations. No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.

9.3 Quality Assurance and Monitoring

Designated personnel from the Coordinating Center will be responsible for maintaining quality assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is conducted appropriately, and the data are generated, documented, and reported in compliance with the protocol that adheres to Good Clinical Practice (GCP) and the applicable regulatory requirements. In addition, QC systems will be in place to ensure that the rights and well-being of trial participants are protected, and that the reported trial data are accurate, complete, and verifiable. Adverse events will be prioritized for monitoring.

A risk-based monitoring (RBM) plan will be developed and revised as needed during the study, consistent with the FDA "Guidance for Industry Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring" (August 2013). This plan describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports.

The data of most importance for monitoring at the site are participant eligibility and adverse events. Therefore, the RBM plan will focus on these areas. As much as possible, remote monitoring will be performed in real-time with on-site monitoring performed to evaluate the veracity and completeness of the key site data.

1292 Elements of the RBM may include:

1293

- 1294 • Qualification assessment, training, and certification for sites and site personnel
- 1295 • Oversight of Institutional Review Board (IRB) coverage and informed consent
- 1296 procedures
- 1297 • Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol
- 1298 review of entered data and edits, statistical monitoring, study closeout
- 1299 • On-site monitoring (site visits): source data verification, site visit report
- 1300 • Agent/Device accountability
- 1301 • Communications with site staff
- 1302 • Participant retention and visit completion
- 1303 • Quality control reports
- 1304 • Management of noncompliance
- 1305 • Documenting monitoring activities
- 1306 • Adverse event reporting and monitoring

1307

1308 Coordinating Center representatives or their designees may visit the study site facilities at any
1309 time to maintain current and personal knowledge of the study through medical record review,
1310 comparison with source documents, observation and discussion of the conduct and progress of
1311 the study. The investigational site will provide direct access to all trial related sites, source
1312 data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and
1313 inspection by local and regulatory authorities.

1314

1315 **9.4 Protocol Deviations**

1316 A protocol deviation is any instance of noncompliance with the clinical trial protocol, GCP, or
1317 clinical procedure requirements. The noncompliance may be either on the part of the participant,
1318 the investigator, or the study site staff. As a result of deviations, corrective actions are to be
1319 developed by the site and implemented promptly.

1320

1321 The site PI, protocol PI (if different) and all study staff are responsible for knowing and adhering
1322 to their IRB requirements. Further details about the handling of protocol deviations will be
1323 included in the monitoring plan.

Chapter 10: Ethics/Protection of Human Participants

1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367

10.1 Ethical Standard

The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.

10.2 Institutional Review Boards

The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the JCHR IRB for review and approval as the IRB of Record. Approval of both the protocol and the consent form must be obtained from the IRB before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. All changes to the consent form will be IRB approved; the IRB will determine whether previously consented participants need to be re-consented.

10.3 Informed Consent Process

10.3.1 Consent Procedures and Documentation

Informed consent is a process that is initiated prior to an individual agreeing to participate in the study and continues throughout that individual's study participation. Written IRB-approved consent materials and consent discussions must be in a language understandable to the participants and their parent(s). For example, if the parent(s) primary language is Spanish, then the Spanish consent form, as well as other participant/parent facing materials (e.g., questionnaires) must be in Spanish. Also, the use of a translator approved by the Coordinating Center is required to support not only the consent process, but also the participants and their parent(s) understanding and communication for the duration of the study.

Extensive discussion of risks and possible benefits of participation will be provided to participants and their families. Consent forms will be approved by the IRB and the parent/legal guardian will be asked to read and review the document. The investigator will explain the research study to the parent and participant and answer any questions that may arise. All parents and participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Parents and participants (old enough to sign per IRB) will have the opportunity to carefully review the written consent form and ask questions prior to signing.

Parents should have the opportunity to discuss the study with their partner or family physician or think about it prior to agreeing to participate. Written informed consent will be obtained from a parent and written or verbal assent from the child (depending on age and IRB requirements) prior to performing any study-specific procedures that are not part of the child's routine care. Participants may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to the family for their records. The rights and welfare of the participants will be protected by emphasizing to them and their parent(s) that the quality of their medical care will not be adversely affected if they decline to participate in this study.

1368 **10.4 Participant and Data Confidentiality**

1369 Participant confidentiality is strictly held in trust by the participating investigators, their staff,
1370 and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological
1371 samples and genetic tests in addition to the clinical information relating to participants.

1372 Therefore, the study protocol, documentation, data, and all other information generated will be
1373 held in strict confidence. No information concerning the study or study data will be released to
1374 any unauthorized third party without prior written approval of the sponsor.

1375
1376 The study monitor, other authorized representatives of the sponsor, representatives of the IRB,
1377 regulatory agencies or company supplying study product may inspect all documents and records
1378 required to be maintained by the investigator, including but not limited to, medical records
1379 (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical
1380 study site will permit access to such records.

1381
1382 The study participant's contact information will be securely stored at each clinical site for
1383 internal use during the study. At the end of the study, all records will continue to be kept in a
1384 secure location for as long a period as dictated by the reviewing IRB, institutional policies, or
1385 sponsor requirements.

1386
1387 Study participant research data, which is for purposes of statistical analysis and scientific
1388 reporting, will be transmitted to and stored at the Jaeb Center for Health Research. This will not
1389 include the participant's contact or identifying information. Rather, individual participants and
1390 their research data will be identified by a unique study identification number. The study data
1391 entry and study management systems used by clinical sites and by Jaeb Center for Health
1392 Research staff will be secured and password protected.

1393
1394 At the end of the study, all study databases will be de-identified and archived at the Jaeb Center
1395 for Health Research.

1396
1397 To further protect the privacy of study participants, a Certificate of Confidentiality will be
1398 obtained from the NIH. This certificate protects identifiable research information from forced
1399 disclosure. It allows the investigator and others who have access to research records to refuse to
1400 disclose identifying information on research participation in any civil, criminal, administrative,
1401 legislative, or other proceeding, whether at the federal, state, or local level. By protecting
1402 researchers and institutions from being compelled to disclose information that would identify
1403 research participants, Certificates of Confidentiality help achieve the research objectives and
1404 promote participation in studies by helping assure confidentiality and privacy to participants.

1405
1406 **10.5 Future Use of Data**

1407 Data collected for this study will be analyzed and stored at the Jaeb Center for Health Research.
1408 After the study is completed, the de-identified, archived data will be made available to the
1409 public.

Chapter 11: References

- 1410
- 1411 1. Holmes JM, Clarke MP. Amblyopia. *Lancet*. 2006;367:1343-51.
- 1412 2. Webber AL, Wood J. Amblyopia: prevalence, natural history, functional effects and
1413 treatment. *Clin Exp Optom*. 2005;88(6):365-75.
- 1414 3. Abraham SV. Accommodation in the amblyopic eye. *Am J Ophthalmol*. 1961;52:197-
1415 200.
- 1416 4. Agrawal R, Conner IP, Odom JV, Schwartz TL, Mendola JD. Relating binocular and
1417 monocular vision in strabismic and anisometric amblyopia. *Arch Ophthalmol*. 2006;(124):844-
1418 50.
- 1419 5. Ciuffreda KJ, Hokoda SC, Hung GK, Semmlow JL, Selenow A. Static aspects of
1420 accommodation in human amblyopia. *Am J Optom Physiol Opt*. 1983;60(6):436-49.
- 1421 6. Kelly KR, Jost RM, De La Cruz A, Birch EE. Amblyopic children read more slowly than
1422 controls under natural, binocular reading conditions. *J AAPOS*. 2015;19(6):515-20.
- 1423 7. McKee SP, Levi DM, Movshon JA. The pattern of visual deficits in amblyopia. *J Vis*.
1424 2003;3(5):380-405.
- 1425 8. Repka MX, Kraker RT, Beck RW, et al. Monocular oral reading performance after
1426 amblyopia treatment in children. *Am J Ophthalmol*. 2008;146(6):942-7.
- 1427 9. Rutstein RP, Corliss D. Relationship between anisometropia, amblyopia, and
1428 binocularity. *Optom Vis Sci*. 1999;76(4):229-33.
- 1429 10. Weakley DR, Jr. The association between nonstrabismic anisometropia, amblyopia, and
1430 subnormal binocularity. *Ophthalmology*. 2001;108(1):163-71.
- 1431 11. Birch EE, Kelly KR. Pediatric ophthalmology and childhood reading difficulties:
1432 Amblyopia and slow reading. *J AAPOS*. 2017;21(6):442-444. doi: 10.1016/j.jaapos.2017.06.013.
1433 Epub 2017 Sep 1.
- 1434 12. Kelly KR, Jost RM, De La Cruz A, et al. Slow reading in children with anisometric
1435 amblyopia is associated with fixation instability and increased saccades. *J AAPOS*.
1436 2017;21(6):447-451.
- 1437 13. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for
1438 treatment of moderate amblyopia in children. *Arch Ophthalmol*. 2002;120(3):268-78.
- 1439 14. Pediatric Eye Disease Investigator Group. Two-year follow-up of a 6-month randomized
1440 trial of atropine vs patching for treatment of moderate amblyopia in children. *Arch Ophthalmol*.
1441 2005;123(2):149-157.
- 1442 15. Pediatric Eye Disease Investigator Group. A comparison of atropine and patching
1443 treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and
1444 other factors. *Ophthalmology*. 2003;110(8):1632-8.
- 1445 16. Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for
1446 treatment of moderate amblyopia in children. *Arch Ophthalmol*. 2003;121(5):603-611.
- 1447 17. Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching
1448 regimens for treatment of severe amblyopia in children. *Ophthalmology*. 2003;110(11):2075-87.
- 1449 18. Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for
1450 treatment of moderate amblyopia in children. *Ophthalmology*. 2004;111(11):2076-2085.
- 1451 19. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for
1452 treatment of moderate amblyopia: follow-up at age 10 years. *Arch Ophthalmol*.
1453 2008;126(8):1039-44.

- 1454 20. Repka MX, Kraker RT, Holmes JM, et al. Atropine vs patching for treatment of moderate
1455 amblyopia: follow-up at 15 years of age of a randomized clinical trial. *JAMA Ophthalmology*.
1456 2014;132(7):799-805.
- 1457 21. Oliver M, Neumann E, Chaimovitch Y, Gotesman N, Shimshoni M. Compliance and
1458 results of treatment for amblyopia in children more than 8 years old. *Am J Ophthalmol*.
1459 1986;102(3):340-5.
- 1460 22. Pritchard C. Why won't you treat my 10 year old's lazy eye? *Am Orthopt J*. 1990;40:15-
1461 18.
- 1462 23. Loudon SE, Polling JR, Simonsz HJ. Electronically measured compliance with occlusion
1463 therapy for amblyopia is related to visual acuity increase. *Graefes Arch Clin Exp Ophthalmol*.
1464 2003;41(3):176-180.
- 1465 24. Stewart CE, Moseley MJ, Stephens DA, Fielder AR, MOTAS Cooperative. Treatment
1466 dose-response in amblyopia therapy: The Monitored Occlusion Treatment of Amblyopia Study
1467 (MOTAS). *Invest Ophthalmol Vis Sci*. 2004;45(9):3048-3054.
- 1468 25. Taylor V, Bossi M, Bunce C, Greenwood JA, Dahlmann-Noor A. Binocular versus
1469 standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight
1470 years. *Cochrane Database Syst Rev*. 2015;2015(8)(CD011347)
- 1471 26. Hess RF, Mansouri B, Thompson B. A new binocular approach to the treatment of
1472 amblyopia in adults well beyond the critical period of visual development. *Restor Neurol*
1473 *Neurosci*. 2010;28(6):793-802.
- 1474 27. Baker DH, Meese TS, Mansouri B, Hess RF. Binocular summation of contrast remains
1475 intact in strabismic amblyopia. *Invest Ophthalmol Vis Sci*. 2007;48(11):5332-8.
- 1476 28. Hess RF, Mansouri B, Thompson B. A new binocular approach to the treatment of
1477 amblyopia in adults well beyond the critical period of visual development. *Restor Neurol*
1478 *Neurosci*. 2010;28(6):793-802.
- 1479 29. Knox PJ, Simmers AJ, Gray LS, Cleary M. An Exploratory Study: Prolonged Periods of
1480 Binocular Stimulation Can Provide an Effective Treatment for Childhood Amblyopia.
1481 *Investigative Ophthalmology & Visual Science*. 2012;53(2):817-824.
- 1482 30. Li J, Thompson B, Deng D, Chan LY, Yu M, Hess RF. Dichoptic training enables the
1483 adult amblyopic brain to learn. *Current Biology*. 2013;23(8):R308-R309.
- 1484 31. Holmes JM, Manh VM, Lazar EL, et al. Effect of a binocular iPad game vs part-time
1485 patching in children aged 5 to 12 years with amblyopia: a randomized clinical trial. *JAMA*
1486 *Ophthalmol*. 2016;134(12):1391-1400.
- 1487 32. Manny RE, Holmes JM, Kraker RT, et al. A Randomized Trial of Binocular Dig Rush
1488 Game Treatment for Amblyopia in Children Aged 4 to 6 Years. *Optom Vis Sci*. 2022;99(3):213-
1489 227
- 1490 33. Roy S, Saxena R, Dhiman R, Phuljhele S, Sharma P. Comparison of Dichoptic Therapy
1491 Versus Occlusion Therapy in Children With Anisometropic Amblyopia: A Prospective
1492 Randomized Study. *J Pediatr Ophthalmol Strabismus*. 2022;8:1-8.
- 1493 34. Jin L, Fang Y, Jin C. Binocular treatment for individual with amblyopia: A systematic
1494 review and meta-analysis. *Medicine (Baltimore)*. 2022;101(27)(e28975)
- 1495 35. Kadhum A, Tan ETC, Levi DM, et al. Barriers to successful dichoptic treatment for
1496 amblyopia in young children. *Graefes Arch Clin Exp Ophthalmol*. 2021;259(10):3149-3157.
- 1497 36. Xiao S, Angjeli E, Wu HC, et al. Randomized Controlled Trial of a Dichoptic Digital
1498 Therapeutic for Amblyopia. *Ophthalmology*. 2022;129(1):77-85

1499 37. Jost RM, Hudgins LA, Dao LM, et al. Randomized clinical trial of streaming dichoptic
1500 movies versus patching for treatment of amblyopia in children aged 3 to 7 years. *Sci Rep*.
1501 2022;12(1):4157

1502 38. Xiao S, Gaier ED, Wu HC, et al. Digital therapeutic improves visual acuity and
1503 encourages high adherence in amblyopic children in open-label pilot study. *J AAPOS*.
1504 2021;25(2):e1-6. .

1505 39. Pediatric Eye Disease Investigator Group. Impact of patching and atropine treatment on
1506 the child and family in the amblyopia treatment study. *Arch Ophthalmol*. 2003;121(11):1625-32.

1507 40. Felius J, Chandler DL, Holmes JM, et al. Evaluating the burden of amblyopia treatment
1508 from the parent and child's perspective. *J AAPOS*. 2010;14(5):389-95.

1509 41. Koklanis K, Abel LA, Aroni R. Psychosocial impact of amblyopia and its treatment: a
1510 multidisciplinary study. *Clin Exp Ophthalmol*. 2006;34(8):743-750.

1511 42. Dixon-Woods M, Awan M, Gottlob I. Why is compliance with occlusion therapy for
1512 amblyopia so hard? A qualitative study. *Arch Dis Child*. 2006;91(6):491-494.

1513 43. Horwood J, Waylen A, Herrick D, Williams C, Wolke D. Common visual defects and
1514 peer victimization in children. *Invest Ophthalmol Vis Sci*. 2005;46(4):1177-1181.

1515 44. Drover JR, Felius J, Cheng CS, Morale SE, Wyatt L, Birch EE. Normative pediatric
1516 visual acuity using single surrounded HOTV optotypes on the Electronic Visual Acuity Tester
1517 following the Amblyopia Treatment Study protocol. *J AAPOS*. 2008;12(2):145-9.

1518 45. Pan Y, Tarczy-Hornoch K, Cotter SA, et al. Visual acuity norms in pre-school children:
1519 the Multi-Ethnic Pediatric Eye Disease Study. *Optom Vis Sci*. 2009;86(6):607-12.

1520 46. Hatt SR, Leske DA, Castañeda YS, et al. Development of pediatric eye questionnaires for
1521 children with eye disease. *Am J Ophthalmol*. 2019;200:201-217.

1522 47. Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the
1523 method of choice for handling missing data in randomized trials? *Stat Methods Med Res*.
1524 2018;27(9):2610-2626.

1525 48. US Food and Drug Administration. *Non-inferiority clinical trials to establish*
1526 *effectiveness: Guidance for industry* 2016. FDA-2010-D-0075. Accessed June 28, 2023.
1527 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials)
1528 [clinical-trials](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials)

1529 49. Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control
1530 the false discovery rate. *Biometrika*. 2006;93(3):491-507.

1531 50. Kleinman LC, Norton EC. What's the Risk? A simple approach for estimating adjusted
1532 risk measures from nonlinear models including logistic regression. *Health Serv Res*.
1533 2009;44(1):288-302.

1534 51. Webber AL, Wood JM, Thompson B, E. BE. From suppression to stereoacuity: a
1535 composite binocular function score for clinical research. *Ophthalmic Physiol Opt*. 2019;39:53-
1536 62.

1537